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The increasing success of congenital heart surgery allows more and more infants with (complex) congenital 
heart disease (CHD) to reach adulthood. Congenital heart disease is the most frequently occurring 
congenital disorder in new-borns, with a birth prevalence of approximately 9/1000 live births worldwide 
and 8/1000 in Europe.1 The prevalence of adults with CHD is 4.09 per 1000 adults in Canada and 
approximately 60% of them are women in the childbearing age, representing the majority of pregnant 
women with heart disease.2,3 
 Most women with CHD have had corrective or palliative surgery. The majority of these women 
have residua and sequelae after surgery.4 Approximately 80% of women who reach childbearing age have 
a pregnancy wish.5 Although many women with CHD tolerate pregnancy well, complication rate is 
considerable.6,7 
Physiological changes in pregnancy
In order to meet the increased maternal and foetal metabolic demands, pregnancy induces changes in 
the cardiovascular system including increases in blood volume, cardiac output, heart rate (preload) and 
decrease in systolic and diastolic blood pressure and systemic vascular resistance (afterload) as well as 
changes in neurohormonal parameters and a hypercoagulable state.8
 In normal pregnancy, plasma volume reaches its maximum of 40% above prepregnancy level at 
the end of the 2nd trimester. Cardiac output (CO) increases during pregnancy up to 50% caused by a rise in 
stroke volume during early pregnancy, while heart rate becomes the major factor in late pregnancy. Mean 
heart rate increases with 10-20 beats in the course of pregnancy, peaking in early third trimester.9,10 (Figure 1) 
Systemic blood pressure in general falls in early and mid pregnancy due to vasodilatation and may return 
to prepregnancy values towards the end of pregnancy.  There is a fall in systemic vascular resistance 
between gestational week 5 with a nadir between weeks 20-32. After week 32 of gestation systemic 
vascular resistance increases again. There is a corresponding decrease in systemic blood pressure in the 
first trimester reaching its nadir at mid-pregnancy. Thereafter, systemic blood pressure rises again to 
prepregnancy levels round term.8,9
 The changes in pre- and afterload are accompanied by remodelling in the ventricles and atria. 
Both atria and ventricles increase in size. Left ventricular (LV) remodelling also manifests as increase in 
LV wall thickness and mass.8,11-13 Mitral, tricuspid, aortic and pulmonic annular diameter increase, which 
may cause some increase of valve regurgitation. Most women remain in sinus rhythm during pregnancy, 
however premature atrial and ventricular complexes may become more frequent as a result of increases in 
chamber size. 
 The ability of a normal heart to adapt to chronic volume overload prevents the central venous 
pressure from increasing in healthy women.14
 In normal pregnancy, deceleration time of the E-wave of trans-mitral flow is longer during the 2nd 
trimester due to a slightly increased resistance to diastolic flow, caused by an increase in left ventricular mass.15 In 






The activated erythropoiesis results in a 20-30% increase in the red blood cell mass to meet the 
maternal and foetal oxygen needs. However, due to a relative larger increase in plasma volume than 
red blood cell mass, pregnant women tend to have anaemia due to hemodilution. 
 Brain natriuretic peptide (BNP) is released in response to ventricular distension due to 
volume overload in pregnancy.16 Like BNP, NT-proBNP values are also higher during pregnancy 
than in non-pregnant controls.17 In addition, NT-proBNP values reveal a dynamic course during 
pregnancy. Elevated NT-proBNP values in the first two trimesters probably represent elevated 
cardiac stress caused by the adaptation of the maternal circulation. The decrease of NT-proBNP 
beginning in the second trimester may possibly reflect the decrease in vascular resistance during the 
second trimester. 
 Pregnancy is associated with several haemostatic changes including a rise in coagulation 
factors, fibrinogen and platelet adhesiveness, but also a decrease in fibrinolysis. This causes a 
hypercoagulable state and increases the risk of thromboembolism. Any pre-existing haemostatic 
disorders associated with the heart defect are at particular risk. These include patients with a Fontan 
circulation, right-to-left shunt and pulmonary hypertension. Women with mechanical prosthetic 
valves are also at higher risk of thromboembolism. 
 Significant rises in central blood volume, blood pressure and cardiac output occur during 
contractions in labour and due to auto-transfusion in the postpartum period, associated with 
uterine involution and resorption of leg oedema. Cardiovascular haemodynamic state returns back 
to prepregnancy state in most women within 6 months postpartum.18,19
Figure 1. Change in heart rate, stroke volume and cardiac output from the non-pregnancy state, during pregnancy 
and the first 14 postnatal days. PP, prepregnancy; PN, postnatal day. (Reproduced from Robson et al.9,20) 
Effect of changes in pregnancy in women with CHD
The cardiovascular changes may not be well tolerated in women with CHD, leading to cardiac 
events such as heart failure and arrhythmia but also leading to offspring events such as intra uterine 
growth retardation (IUGR), prematurity and death. Not only volume overload may induce adverse 
events in the offspring, a reduced plasma volume expansion has also been associated with IUGR and 
low birth weight.21 
 The required increase in CO aggravates the haemodynamic burden in women with CHD. This is 
especially important in women with obstructive lesions, since CO in these women is relatively fixed.22.6,23 
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Women with aortic and mitral regurgitation, left to right shunts, as well as women with a right 
systemic ventricle, may benefit from pregnancy related fall in systemic vascular resistance. However, 
the fall in systemic vascular resistance may cause right to left shunts to increase during pregnancy, 
leading to increased dyspnoea and cyanosis as well as adverse events in the offspring.  In women 
with CHD, the pre-existing burden of pressure or volume overload may prevent the ventricles to 
increase CO or require increased filling pressure to do so, especially when concomitant ventricular 
dysfunctions exist. This may result in heart failure during pregnancy. Significant ventricular 
dysfunction already present before pregnancy is associated with a high risk of adverse outcome.6,23 
 Increases in atrial size may contribute to an increase in the frequency of supraventricular 
arrhythmias. Women with a history of arrhythmia prepregnancy are at increased risk of adverse 
cardiac events during pregnancy as has been demonstrated in women with tetralogy of Fallot.5-7,23
BNP levels in women with heart disease are higher than in healthy women. Moreover, BNP levels 
≤100 pg/ml have a negative predictive value of 100% for identifying events during pregnancy.24 
 In the peri- and postpartum periods maternal heart failure may develop due to significant 
rises in blood volume and cardiac output during contractions in labour and auto-transfusion in the 
postpartum period. 
Pregnancy outcome in women with CHD
The haemodynamic changes in the course of pregnancy are associated with increased risk in women 
with CHD. Heart disease is the most common cause of maternal death and the leading non-obstetric 
cause in the United Kingdom. However, only 6 per cent of these deaths are related to maternal 
congenital heart disease.25,26 In the Netherlands, maternal death caused by cardiovascular diseases is 
the 2nd most frequent cause after preeclampsia, followed by death as a result of thromboembolism. 
CHD causes 13% of maternal cardiovascular deaths in the Netherlands.
 Outside pregnancy, most frequent cardiac problems in women with CHD are heart rhythm 
disorders, heart failure, endocarditis, obstructions of conduits and valve dysfunction.27 Most frequent 
pregnancy related cardiac problems are heart failure, heart rhythm disorders and thromboembolism. 
Pregnant women with CHD are not only more susceptible to cardiac complications such as heart 
failure and arrhythmias, also obstetric complications such as hypertensive disorders of pregnancy 
(pregnancy induced hypertension and preeclampsia), premature delivery and offspring complications, 
such as offspring death, small for gestational age and recurrence of CHD in the offspring are more 
frequent. 6,7,23
 Most adverse events can be prevented, or effectively treated provided risk factors are 
recognized timely. To do so, it is important to predict potential adverse events in advance both for 
the mother and the offspring. 
Predictors of adverse pregnancy outcome






left heart obstruction, reduced systemic ventricular function and mechanical valve prosthesis, have 
been identified. Table 1 gives an overview of the predictors of cardiovascular events in pregnancy in 
women with heart disease, as identified in the world literature. Independent risk factors for offspring 
events in women with CHD are also found. (Table 2) Not only the specific CHD related risk 
factors influence pregnancy outcome, generally known predictors for adverse pregnancy outcome 
such as age, parity, maternal diabetes, hypertensive disorders of pregnancy and smoking also apply 
to women with CHD. Although predictors may help to identify women at risk for adverse events 
in pregnancy, it should be kept in mind that the applicability of these predictors depends on the 
population selected. 
Risk stratification
Several models are available to assess the risk of pregnancy in women with CHD. The best know and 
most widely used model to predict cardiac outcome was introduced by the CARPREG investigators.6 
(Table 1) The CARPREG risk score is based on both CHD and acquired heart disease, resulting 
in an overestimation of cardiovascular risk of pregnancy in women with CHD. Another way to 
assess risk of pregnancy is by classification of the complexity of CHD.28,29 Women with complex 
congenital heart disease are known to have higher frequencies of cardiovascular events in pregnancy.7 
The complexity of heart disease however does not take into account the current cardiac function, 
previous events or complicating factors such as aortic diameter in women with bicuspid aortic valve 
or Marfan’s syndrome.
 The ESC guidelines recommend that maternal risk should be assessed according to a 
modified World Health Organization risk classification.34,35 The group in whom pregnancy should 
be avoided and the low risk group in whom pregnancy is expected to be well tolerated are well 
defined. The groups in whom risk of pregnancy is mildly or mildly to moderately elevated is less well 
defined and sometimes needs an expert to assess. No CHD specific prediction model was available 
so far.
15





Prior cardiac event (heart failure, TIA, stroke, arrhythmia) CARPREG6 CHD, AHD 1
NYHA functional class III/IV or cyanosis (SpO2 <90%) CARPREG CHD, AHD 1
Left heart obstruction CARPREG CHD, AHD 1
(MVA <2 cm² or AVA <1.5 cm² or peak LVOT gradient >30 mmHg
Reduced systemic ventricular systolic function (EF <40%) CARPREG CHD, AHD 1
ZAHARA
History of arrhythmia ZAHARA23 CHD 1.50
NYHA functional class III/IV ZAHARA CHD 0.75
Left heart obstruction (peak LVOT gradient >50 mmHg or AVA <1.0 cm²) ZAHARA CHD 2.50
Mechanical valve prosthesis ZAHARA CHD 4.25
Systemic AV valve regurgitation (moderate/severe) ZAHARA CHD 0.75
Pulmonary AV valve regurgitation (moderate/severe) ZAHARA CHD 0.75
Cardiac medication before pregnancy ZAHARA CHD 1.50
Cyanotic heart disease (corrected and uncorrected) ZAHARA CHD 1.00
OTHER STUDIES
Prior cardiac event (heart failure, TIA, stroke, arrhythmia) Tanous24 CHD, AHD
Cardiac medication before pregnancy Tanous CHD, AHD
Anticoagulation therapy Tanous CHD, AHD
Maximum BNP >100 pg/ml Tanous CHD, AHD
Right ventricular dilatation Song30 CHD
Pulmonary arterial hypertension Song CHD
NYHA functional class III/IV Song CHD
NYHA functional class III/IV Kovavisarach31 CHD, AHD
Smoking history Khairy32 CHD
Reduced sub-pulmonary ventricular function and/or severe PR Khairy CHD
CARPREG risk score: For each CARPREG predictor that is present, 1 point is assigned to the pregnancy. The risk score is the 
total number of points. The risk of maternal cardiovascular complications is 5% with 0 points, 27% with 1 point and 75% 
with ≥1 point.
ZAHARA risk score: For each ZAHARA predictor that is present, a predictor-specific number of points is assigned to the 
pregnancy, according to the table. The risk of maternal cardiovascular complications is 2.9% with <0.5 points, 7.5% with 
0.5–1.5 points, 17.5% with 1.51–2.50 points, 43.1% with 2.51–3.5 points and 70% with >3.5 points. 
AHD, acquired heart disease; AV, atrioventricular; AVA, aortic valve area; BNP, B-type natriuretic peptide; CHD, congenital 
heart disease; EF, ejection fraction; LVOT, left ventricular outflow tract; MVA, mitral valve area; NYHA, New York Heart 
Association; PR, pulmonary regurgitation, SpO
2, Saturation of Haemoglobin with Oxygen as measured by Pulse Oximetry; 











NYHA functional class III/IV or cyanosis (SpO
2
 <90%) CARPREG 6 CHD, AHD
Heparin / Warfarin use during pregnancy CARPREG CHD, AHD
Smoking during pregnancy CARPREG CHD, AHD
Multiple gestation CARPREG CHD, AHD
Left heart obstruction CARPREG CHD, AHD
(MVA <2 cm² or AVA <1.5 cm²or peak LVOT gradient >30 mmHg
ZAHARA
Mechanical valve prosthesis ZAHARA 23 CHD 2.50
Twin or multiple gestation ZAHARA CHD 1.75
Cyanotic heart disease (corrected and uncorrected) ZAHARA CHD 0.75
Cardiac medication before pregnancy ZAHARA CHD 0.75
Smoking during pregnancy ZAHARA CHD 0.50
OTHER STUDIES
Subaortic ventricular outflow tract gradient > 30 mmHg Khairy 32 CHD
Myocardial dysfunction* Gelson 36 CHD, AHD
Pulmonary hypertension Song 30 CHD
NYHA functional class III/IV Song CHD
ZAHARA risk score: For each ZAHARA predictor that is present, a predictor-specific number of points are assigned to the 
pregnancy, according to the table. The risk of offspring complications is 19.9% with <0.5 points, 33.3% with 0.5–1.0 points, 
46.7% with 1.00–1.50 points and 59.5% with >1.5 points. 
AHD, acquired heart disease; AVA, aortic valve area; CHD, congenital heart disease; LVOT, left ventricular outflow tract; 
MVA, mitral valve area; NYHA, New York Heart Association; PR, pulmonary regurgitation, SpO
2, Saturation of 
Haemoglobin with Oxygen as measured by Pulse Oximetry 
* Unspecified 
ZAHARA I study
To give disease specific insights in the complications women with CHD encounter during 
pregnancy and to investigate the magnitude and determinants of risks associated with pregnancy 
in specific groups of women with CHD, the first ZAHARA study was set up. For this purpose, 
a total of 1302 pregnancies in 1802 women with CHD were observed in retrospect.23 The ZAHARA I 
study revealed some disease specific predictors of adverse pregnancy outcome.5,23,37-40 In this thesis, we 
introduce predictors for maternal cardiovascular and offspring complications in women with tetralogy 
of Fallot.5 In addition, we introduce a specific model for pregnancy in women with CHD in general 
and validate this model. To give a complete overview, this model is included in table 1. 
17
The abovementioned prediction models by the CARPREG investigators and our own prediction 
model as well as individual predictors found by others (Table 1) may allow refining of risk assessment 
in women with CHD. It is important that CHD specific risk assessment and counselling is done 
before women with CHD become pregnant so that a pregnancy management plan, including changes 
in medication, planning of follow-up visits (during pregnancy) and the mode and location of delivery 
can be made.
Role of cardiac function in prediction of uteroplacental Doppler flow
In normal pregnancy, a gradual widening of the maternal spiral arteries occurs early in the first 
trimester due to the invasion of endovascular and interstitial trophoblasts that convert maternal spiral 
arteries closer to the intervillous space. To maintain adequate organ and uteroplacental perfusion, 
haemodynamic changes such as increased plasma volume and CO and decreased systemic vascular 
resistance must take place. During normal pregnancy, blood flow increases in the low impedance 
uteroplacental circulation, reaching up to 500ml/min at term. Placental flow increase until gestational 
week 25 and then remains unchanged.41 Reduced invasion and subsequent remodelling of maternal 
spiral arteries in the first and second trimester lead to an impaired placental perfusion and release 
of factors into the maternal circulation resulting in endothelial cell damage leading to hypertensive 
disorders of pregnancy, which affects 6-10% of pregnancies.42 Hypertensive disorders of pregnancy, 
especially preeclampsia, are characterized by impaired trophoblasts invasion and failure of dilatation of 
spiral arteries, resulting in high uteroplacental vascular resistance, leading to inadequate uteroplacental 
perfusion and adverse obstetric and offspring outcome.43,44 Moreover, poor trophoblast invasion and 
abnormal uteroplacental Doppler flow is associated with cardiovascular dysfunction.45,46
 Compromised uterine perfusion with placental dysfunction is reflected by abnormal 
uteroplacental Doppler flow patterns.47 Uterine artery pulsatility index (PI) and resistance index (RI) 
are associated with CO, stroke volume, left ventricular isovolumetric relaxation time (IVRT) and 
systemic vascular resistance.15 Abnormal uterine artery PI/RI as well as the presence of a notch in 
early diastolic phase predict preeclampsia, are related to high systemic vascular resistance and low 
CO, and are associated with adverse outcome in the offspring such as IUGR and small for gestational 
age, dysmaturity and low birth weight. In CHD, a higher incidence of preeclampsia and IUGR is 
seen.6,7,23,32,48,49 This may be related to the impaired cardiac function in women with CHD, leading to 
a lower CO and to an inadequate uteroplacental perfusion. 
Objectives of this thesis
The main objectives of this thesis are to identify predictors of adverse outcome in pregnancies of women 
with CHD, to assess the best currently available model to predict pregnancy outcome and to elucidate 
the mechanism behind the high incidence of offspring events in pregnancies of women with CHD, in 






Outline of this thesis
Part I addresses in retrospect complications and predictors of adverse pregnancy events in women 
with CHD. In chapter two pregnancy outcome as well as predictors of adverse outcome are described 
in women with tetralogy of Fallot; one of the larger groups of CHD patients. In chapter three an 
overview is given of complications and predictors for the total group of women with CHD. In 
addition, the most frequently used  prediction model for the estimation of pregnancy risk in women 
with heart disease is validated and compared with a newly developed CHD-specific pregnancy risk 
model. 
Part II covers the prospective assessment of predictors of adverse events in pregnancy in women 
with CHD. Chapter four provides the design and rationale of the prospective multicentre 
ZAHARA II study and in chapter five the various available risk estimation models are validated and 
mutually compared using the ZAHARA II population. Chapter six describes the main outcomes of 
the ZAHARA II study: the difference in cardiovascular, clinical, biochemical and echocardiographic 
parameters, the difference in uteroplacental Doppler flow patterns as well as difference in outcome 
between pregnant women with CHD and healthy pregnant women. In addition, the relation 
between the maternal cardiac function in women with CHD and the uteroplacental Doppler 
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Background In women with corrected tetralogy of Fallot (ToF), pregnancy is associated with 
maternal cardiac, obstetric, and offspring complications. Our aim is to investigate the magnitude 
and determinants of pregnancy outcome in women with corrected ToF. 
Methods In this retrospective international multicenter study using 2 congenital heart disease 
registries, 204 women with corrected ToF were identified. Within this group, 74 women had 157 
pregnancies, including 30 miscarriages and 4 terminations of pregnancy. Detailed information 
on each completed pregnancy (n=123) was obtained using medical records and supplementary 
interviews.
Results Cardiovascular events occurred during 10 (8.1%) pregnancies, mainly (supra)ventricular 
arrhythmias. Obstetric and offspring events occurred in 73 (58.9%) and 42 (33.9%) pregnancies, 
respectively, including offspring mortality in 8 (6.4%). The most important predictor was use of 
cardiac medication before pregnancy (odds ratio for cardiac events 11.7, 95% CI 2.2-62.7; odds ratio 
for offspring events 8.4, 95% CI 1.4-48.6). In pregnancies with cardiovascular events, significantly 
more small-for-gestational-age children were born (P value < 0.01).
Conclusions Cardiovascular, obstetric, and offspring events occur frequently during pregnancies in 
women with ToF. Maternal use of cardiovascular medication is associated with pregnancy outcome, 
and maternal cardiovascular events during pregnancy are highly associated with offspring events.
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Introduction
Long-term survival after correction of tetralogy of Fallot (ToF) is excellent.1 Pregnancy is generally 
well tolerated in women with corrected ToF.2 Nevertheless, cardiac, obstetric, and offspring events 
occurred, respectively, during 4.5% to 18%, 11% to 20% and 16% to 27% of completed gestations.3-7 
Predictors of adverse outcome in a cohort with ToF are not known; but in a mixed congenital heart 
disease (CHD) population, severe pulmonary regurgitation (PR) and right ventricular dysfunction 
were independent predictors of cardiac events during pregnancy.5 Whether or not pulmonary valve 
replacement (PVR) before pregnancy influences pregnancy outcome is unknown. The primary 
objective of the present study is to determine the magnitude and the nature of events encountered 
during pregnancy in women with corrected ToF. Secondary objectives are to identify predictors of 
adverse pregnancy outcome as well as to investigate whether or not cardiac events could influence 
offspring outcome during the same pregnancy.
Patients and Methods
For the present study, all female patients with ToF aged 18 to 58 years enrolled in the nationwide 
CONgenital CORvitia (CONCOR) registry and a Belgian tertiary medical center’s adult CHD 
database were identified and asked to participate in the study.8,9 The institutional review board 
or ethics committee at each of the participating tertiary centers approved the protocol. Data 
were obtained from medical records, and supplementary data were retrieved by a questionnaire. 
Baseline data included basic cardiac anatomy, history, and electrophysiology; prior cardiac events 
using the European Pediatric Cardiac Coding; noncardiac comorbidity; maternal age at inclusion; 
prepregnancy New York Heart Association (NYHA) functional class and cyanosis (oxygen saturation 
<90%); the use of medication; use of cigarettes, drugs, and/or alcohol; and obstetric history including 
miscarriages (spontaneous fetal loss <20 weeks of gestation) and/or elective abortions.10-12 Detailed 
information concerning each completed pregnancy (>20 weeks of gestation) between 1980 and 
2007 was recorded: maternal age at conception; mode of delivery; parity; use of cigarettes, drugs, 
and/or alcohol during pregnancy; use of medication; change in NYHA functional class; 12-leads 
electrocardiogram; transthoracic echocardiograms; and/or 24-hour electrocardiogram (Holter) 
registrations. Documented pregnancy-related events were divided into cardiovascular, obstetric, and 
offspring events (composite endpoints).
Cardiovascular events
Cardiovascular events were defined as follows: documented symptomatic arrhythmia or heart failure 
requiring treatment (according to attending cardiologist), myocardial infarction, endocarditis, aortic 
dissection, thromboembolic events, and/or stroke.
Obstetric events






gestation, ≥140 mmHg systolic and/or ≥90 mmHg diastolic blood pressure, without proteinuria); 
preeclampsia (PIH with ≥0.3 g of proteinuria in a 24-hours urine sample); eclampsia (preeclampsia 
with grand mal seizures); hemolysis elevated liver enzymes low platelets syndrome; gestational 
diabetes13; hyperemesis gravidarum (severe, intractable nausea and vomiting leading to dehydration, 
loss of weight, metabolic disorders, and/or hospitalization); preterm prelabor rupture of membranes 
(PPROM); assisted delivery (use of forceps or vacuum extraction); caesarean delivery on medical 
indication; prolongation of cervix ripening (omitted dilatation of the portio vaginalis for ≥20 
hours (nullipara) or ≥14 hours (multipara), despite adequate and regular uterus contractions); 
prolongation of second stage of delivery (primipara >2 hours or multipara >1 hour); premature labor 
(PL; spontaneous onset of labor at <37 weeks of gestation); postpartum hemorrhage (PPH; blood 
loss at vaginal delivery ≥500 mL or caesarean delivery ≥1000 mL).
Offspring events
Offspring events were defined as follows: premature birth (birth <37 weeks of gestation); small-for-
gestational-age (SGA; birth weight <10th percentile); fetal mortality (intrauterine death ≥20 weeks of 
gestation); offspring death (within the first year after birth); and/or iteration of CHD.
Statistical analysis
A Clintrial data entry program was used to record information and was converted to SPSS 
(version 16.0; SPSS Inc, Chicago, IL) for statistical analysis. Descriptive statistics for nominal data 
are expressed in absolute numbers and percentages. Mean values and SD are presented for normally 
distributed continuous variables. For nonnormally distributed continuous variables, median and 
interquartile ranges were computed. Comparison of continuous variables between groups was 
made by unpaired Student’s t tests or Mann-Whitney U test depending on distribution. For the 
comparison of dichotomous variables, we used the Χ 2 test or Fisher exact test, where applicable. 
All P values presented are two-sided. Univariable logistic regression analysis was performed to identify 
predictors of adverse pregnancy outcome, divided into 3 composite end points (as defined above): 
cardiac, obstetric, and offspring events. The following prepregnancy baseline variables were assessed: 
palliative surgery before ToF correction, history of arrhythmias, PVR, use of cardiac prescription 
medication, NYHA functional class, the presence of a patent shunt, pulmonary atrioventricular 
valve regurgitation (moderate/severe), pulmonary valve regurgitation (PR; moderate/severe) and/
or right ventricular outflow tract obstruction (peak gradient >50 mmHg), and reduced systemic 
ventricular function. For the classification of valve regurgitation and valve stenosis, we used the 
classification as recommended by the European Society of Cardiology and the American Society 
of Echocardiography in their guidelines on valvular heart disease.14,15 Variables that were associated 
with an increased incidence of the studied end points (P<0.10) entered the multivariable stage, 
which at least contained the variables age and parity. The final multivariable model was then 
constructed by backward deletion of the least significant characteristic until all remaining variables 
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were significantly (P <0.05) associated with the end point. Because some women went through >1 
pregnancy, the validity of treating each pregnancy as an independent event was confirmed by general 
estimating equation analysis. 
Funding
This work was supported by Netherlands Heart Foundation grant 2002B125. The authors are solely 
responsible for the design and conduct of this study, all study analyses, the drafting and editing of 
the paper, and its final contents. 
Results
Written informed consent was provided by 204 women (82% of all women who were asked to 
participate) with corrected ToF. We observed 157 pregnancies in 74 of these patients. One third 
of the ToF women were enrolled in a pilot study published previously.3 Of the 157 pregnancies, 
30 ended in a miscarriage (19%) and 4 in an elective abortion (2.5%), leaving 123 completed 
pregnancies (≥20 weeks of gestation, including 1 twin pregnancy) in 69 different patients. From the 
16 women who had 30 miscarriages, 13 women later had completed pregnancies. Table 1 shows the 
baseline characteristics of women with and without completed pregnancies. 
Women without completed pregnancies were younger and more often had a mental disability. 
Most ToF women had a desire for children (168 of 204; 82%). In the childless cohort, the most 
common reason for being childless at inclusion was that women felt too young (not ready) to have 
children (n=51; 38%). Thirteen patients reported that anticipated cardiovascular events were the 
reason they did not pursue pregnancy (9.6%), and 6 of them were advised against pregnancy by their 
cardiologist. Three women (2.2%) did not have children because of concerns regarding heredity of 
ToF. 
Because the available data concerning the incomplete pregnancies were very limited, we further 
focused on the 123 completed pregnancies. In Table 2 the baseline characteristics of the 123 
completed pregnancies are presented. Of the pregnancies in our cohort, 19.5% was observed before 
1990. Between 1990 and 2000, 49.6% and, after 2000, 30.9% of the pregnancies took place. 
There was no relation between pregnancy period and cardiovascular, obstetric, or offspring outcome. 
Thirty-three women had undergone PVR at a median age of 23.5 years (range 7-33 years).
None of the patients in our cohort had cyanosis. In 30 of 123 pregnancies (24%), the mother 
smoked before pregnancy; and in 20 of 123 pregnancies (16%), the mother continued smoking 
during pregnancy. Details regarding events that were encountered during completed pregnancies are 



















Mean age at inclusion, y  (± SD) 31 ± 7.5 28 ± 6.7 36 ± 5.8 < 0.001
Mean age at repair, y (± SD) 5.1 ± 2.7 4.7 ± 2.5 6.1 ± 2.8 < 0.001
Surgeries before or after repair (%)
 Blalock -Taussig shunt 22 (10.8) 15 (11.1) 7 (10.1) NS
 Waterston shunt 29 (14.2) 14 (10.4) 15 (21.7) <0.05
 Potts Shunt 2 (1.0) 0 (0.0) 2 (2.9) NS
 RVOT procedure 42 (20.6) 24 (17.8) 18 (26.1) NS
 PVR 44 (21.6) 26 (19.3) 18 (26.1) NS
Valvular dysfunction (%)
 Tricuspid regurgitation‡ 27 (18.5) 15 (18.1) 12 (19.0) NS
 RVOT obstruction 46 (31.5) 21 (25.3) 25 (39.7) NS
 Pulmonary valve regurgitation‡ 77 (52.7) 39 (47.0) 38 (60.3) NS
Ventricular septal defect (%) 13 (8.9) 6 (4.4) 7 (11.1) NS
Mental disability (%) 12 (5.9) 12 (8.9) 0 (0.0) <0.01
PVR, Pulmonary valve replacement; RVOT, Right ventricular outflow tract; NS, not significant (P >0.05).
* Completed pregnancy, lasting >20 weeks.
† Comparison of women without completed pregnancies versus women with completed pregnancies.
‡ Moderate or severe.15
Cardiovascular outcome 
The most frequent cardiovascular events were clinically significant arrhythmias needing treatment, 
which occurred during 8 pregnancies (6.5%); in 4 pregnancies, the mother had atrial fibrillation 
or flutter; and in the other 4 pregnancies, the mother had symptomatic ventricular tachycardias. 
Two of these patients had a history of arrhythmias. Heart failure developed during 2 pregnancies 
(1.6%), both during the third trimester and in the context of severe PR; one of these women had 
undergone PVR. Pulmonary embolism was diagnosed and subsequently treated with low–molecular 
weight heparin in one pregnancy. Deterioration of NYHA functional class (≥1 class, between 
prepregnancy and the third trimester) was documented in 22 completed pregnancies (17.7%) and 
persisted post pregnancy in 3 pregnancies (2%). Myocardial infarction, stroke, or aortic dissection 
did not occur in this cohort.
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Table 2. Baseline characteristics of the 123 completed pregnancies* in women with corrected ToF.
N=123
Mean age at inclusion, y (±SD) 36.4 ± 5.6
Mean age at repair, y (±SD) 6.5 ± 4.2
Surgery before/after repair, n (%)
 Blalock-Taussig shunt 12 (9.8)
 Waterston shunt 22 (17.9)
 Potts shunt 2 (1.6)
 RVOT procedure 47 (38.2)
 PVR 33 (26.8)
Valvular dysfunction, n (%) 
 Tricuspid regurgitation (moderate/severe)15 25 (20.3)
 RVOT obstruction 54 (43.9)
 Pulmonary valve regurgitation (moderate/severe)15 69 (56.1)
Ventricular septal defect, n (%) 20 (16.3)
History of arrhythmias, n (%) 5 (4.1)
History of heart failure, n (%) 3 (2.4)
NYHA class ≥II prepregnancy, n (%) 8 (6.5)
Cardiac medication used prepregnancy, n (%) 7 (5.7)
 β-Blockers† 1 (0.8)
 Calcium-channel blockers 1 (0.8)
 Digoxin 3 (2.4)
 Amiodarone 2 (1.6)
Vitamin K antagonists, n (%) 2 (1.6)
Mean age at pregnancy, y (±SD) 26.8 ± 4.1
Primipara, n (%) 32 (26.0)
Multipara, n (%) 91 (74.0)
Mean pregnancy duration, wk (±SD) 37.8 ± 4.5
* Completed pregnancy, lasting >20 weeks. 












Cardiovascular events 10 (8.1)
 Arrhythmias 8 (6.5) <1
 Heart failure 2 (1.6) <1
 Thromboembolic events 1 (0.8) <0.3
Obstetric events 73 (58.9)
 Caesarean delivery 25 (20.3) 6.5
 Assisted† vaginal delivery 16 (13.0) 17
 PPH 12 (9.7) 2.9
 Prolongation of 2nd stage of delivery 10 (8.1) <2.7
 PPROM 8 (6.5) 1.5
 PIH 6 (4.8) 10
 Prolongation of cervix ripening 5 (4.1) –
 Preeclampsia 4 (3.2) 1.4
 Hyperemesis 2 (1.6) 0.6
 Solutio placentae 1 (0.8) <1
 Uterus rupture 1 (0.8) <0.001
Offspring events 42 (33.9)
 SGA 23 (18.5) 10
 PB 22 (17.7) 10
 OM 8 (6.4) 0.9
 CHD 3 (2.4) 0.6
 Other offspring events‡ 3 (2.4) –
PB, Preterm birth; OM, offspring mortality. 
* Completed pregnancy, lasting >20 weeks. 
† Delivery assisted using forceps or vacuum extraction. 
‡ Other offspring events were fetal asphyxia, trisomy 13, and hydrocephalus. 
§ Normal population, based on literature.4,24,25,27-29,32,33
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Table 4. Results of univariable and multivariable logistic regression models and corresponding risk 
scores for cardiac, obstetric, and offspring events.
Univariable analysis
Cardiovascular events* Obstetric events* Offspring events*
Palliative surgery 1.3 (0.3-5.1) 0.8 (0.4-1.7) 2.7 (1.1-6.2)‡
History of arrhythmias 9.3 (1.8-46.9)‡ 5.2 (0.6-43.6) 2.0 (0.5-8.5)
Prior PVR 3.1 (0.8-11.4)† 2.2 (0.9-5.3)† 1.4 (0.6-3.2)
RVOT obstruction 0.9 (0.2-3.2) 1.2 (0.6-2.4) 1.3 (0.6-2.7)
Pulmonary valve regurgitation§ 0.5 (0.1-1.9) 0.5 (0.23-0.99)‡ 1.3 (0.6-2.7)
Pulmonary AV valve regurgitation 0.6 (0.1-2.3) 1.4 (0.6-3.4) 2.1 (0.9-5.2)†
Patent shunt 0.8 (0.1-3.8) 2.5 (0.9-6.7) 1.1 (0.4-2.9)
Smoking during pregnancy 0.8 (0.1-3.8) 0.9 (0.4-2.5) 1.4 (0.5-3.7)
Use of cardiac medication prepregnancy 11.8 (2.2-63.3)‡ – 5.5 (1.0-29.2)‡
NYHA class III/IV 0.6 (0.1-5.3) – 0.3 (0.0-2.7)
Multivariable analysis for endpoints cardiovascular, obstetric and offspring events
Odds ratio (95% CI)
Cardiovascular events
Use of cardiac medication prepregnancy 11.7 (2.2 – 62.7)‡
Obstetric events
Pulmonary valve regurgitation 0.5 (0.2 – 0.99)‡
Offspring events
Palliative surgery 3.3 (1.3 – 8.2)‡
Use of cardiac medication prepregnancy 8.1 (1.4 – 48.6)‡
AV, Atrioventricular. 
* Expressed as OR (95% CI). 
† P <0 .1. 
‡ P <0.05. 
§ Moderate or severe.14,15
Obstetric outcome
Caesarean delivery was the most frequently observed obstetric event and was necessary in 20.3% 
of completed pregnancies (n=25). A “primary” (planned) caesarean delivery was carried out during 
16 gestations, 5 of which were executed based on maternal cardiac indication (moderate/severe 
pulmonary valve stenosis or regurgitation combined with tricuspid regurgitation and high risk of 
arrhythmia). Nine “secondary” (unscheduled) caesarean deliveries were performed, all on obstetric 
indication. Postpartum hemorrhage, hypertensive disorders of pregnancy, and PPROM complicated, 
respectively, 9.7%, 8%, and 6.5% of completed pregnancies. Forceps were used in 3 pregnancies; 
and in 13 pregnancies, a vacuum extractor was used to assist vaginal delivery. No significant time 







The median birth weight was 3100 g (25th percentile 2755 g; 75th percentile 3400 g). Twenty-three 
children (19%) were SGA. Delivery was preterm in 22 (18%) of the completed pregnancies. Iteration 
of CHD was diagnosed in 3 (2.4%) children. In one child, the cardiac defect (atrial septal defect) 
was associated with a trisomy 13; the other two children had tetralogy of Fallot and atrioventricular 
septal defect respectively. The overall offspring mortality was 6.4%. Intrauterine demise occurred 
during 5 gestations, and 3 children died within the first year postpartum. The main reasons for 
offspring death were immaturity and/or prematurity at birth, intrauterine growth restriction, and 
recurrence of CHD. Also for offspring outcome, no time effect could be detected. The occurrence of 
cardiovascular events was associated with a significantly higher number of SGA children (in 5 of 10 
pregnancies with cardiovascular events, the offspring was SGA versus 18 of 114 pregnancies without 
cardiovascular events [P<0.01]).
Predictors
The univariable and multivariable predictors for the composite end points are shown in table 4. 
Prior PVR was strongly associated with cardiovascular events. Mainly arrhythmias (n=4) 
complicated pregnancies in the PVR group. In one pregnancy, pulmonary embolism was 
observed; and one pregnancy in the PVR group was complicated with arrhythmia as well as with 
heart failure. Arrhythmias before pregnancy were highly associated with cardiovascular events. 
The most important independent predictor for cardiovascular as well as offspring events was the use 
of cardiac medication before pregnancy. In pregnancies of women who used any cardiac medication 
before pregnancy, the risk for SGA babies was almost 7-fold higher compared with pregnancies of 
women without history of cardiac medication use (odds ratio [OR] 6.8, 95% CI 1.4-32.9, P=0.02). 
None of the specific cardiac medication used before pregnancy stood out as a culprit. Use of any 
cardiac medication during pregnancy had a high association with SGA, but this was not statistically 
significant (OR 4.9, 95% CI 0.9-25.8, P=0.06). No association was found between SGA and other 
known causes, such as PIH or PE, in our cohort. The use of cardiac medication before pregnancy 
was associated with PVR: 5 of 7 women who used cardiac medication before pregnancy had previous 
PVR. Another independent predictor of offspring events was palliative surgical intervention before 
correction. Women with moderate to severe pulmonary valve regurgitation seem to encounter less 
obstetric events (35 of 69 vs. 38 of 54, P=0.04).
Discussion
Women with corrected ToF are at increased risk of cardiovascular and obstetric events during 
pregnancy. Most events are well treatable. The incidence of offspring events is markedly increased. 
Cardiovascular and offspring outcomes are strongly related with the use of cardiac medication 
before pregnancy. Surgical status before pregnancy also appears to predict pregnancy outcome. 
Offspring events are related to maternal cardiovascular events. In our cohort, 19% of the pregnancies 
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ended in a spontaneous abortion, which is slightly higher than in healthy women (10%-16%) 
and slightly higher than reported previously in pregnancies of women with ToF.4,16 
Cardiovascular outcome
The occurrence of cardiovascular events in the present study is comparable to that reported in a recent 
literature review, which described the outcome of 200 pregnancies in patients with corrected ToF.4 
Arrhythmias were the major cardiac event. Arrhythmias before pregnancy predicted cardiovascular 
events, as described previously.6,17-19 Supraventricular and ventricular arrhythmias are well-known 
long-term sequelae of intracardiac repair of ToF.20,21 The use of cardiac medication before pregnancy 
strongly predicted cardiovascular events. This predictor probably reflects a less favorable cardiac 
condition in terms of ventricular function and arrhythmias. In contrast to others, we did not observe 
a relationship between severity of PR and more adverse events.5,7 In previous publications, it was 
likely that PR was associated with worse pregnancy outcome especially when it was associated with 
right ventricular dysfunction.7,22 Heart failure occurred only twice in our population, both times in 
women with severe PR. The most prevalent complications were arrhythmias, which are related not 
only to hemodynamics but also to surgical scars and therefore may be encountered also in women 
with an adequate haemodynamic situation but with a history of surgery, as in women with corrected 
ToF. 
Pulmonary valve replacement was associated with worse cardiovascular outcome, which is 
counterintuitive. The use of cardiac medication before pregnancy was strongly associated with PVR 
(71% of all women who used cardiac medication had PVR), indicating a less favorable cardiac 
condition in the PVR group. This might be related to late timing of PVR, as all PVRs were 
performed between 1990 and 2000, when early timing of PVR was not routinely applied. Therefore, 
in most of these patients, PVR was likely performed when right ventricular function was already 
compromised. A recent study showed progression of RV dilatation that persisted postpregnancy in 
women with corrected ToF, which could not be demonstrated in comparable women who did not 
have pregnancies.23 In our study, the main events in women after PVR were arrhythmias. These 
patients may have been vulnerable to arrhythmias because of right ventricular dysfunction, but 
surgical scars may have also played a role in the occurrence of arrhythmias. In addition, several 
women had arrhythmias prepregnancy, which is a known predictor for arrhythmias during 
pregnancy.6 Unfortunately, our study does not answer the question if timely prepregnancy PVR 
would have prevented cardiovascular pregnancy events in women with ToF.
Obstetric outcome
The most important obstetric events were PPH and PL based on rupture of membranes, which 
occurred more frequently than described previously in population-based studies (2.9% and 
1.5%, respectively).24,25 No direct explanation was found; more specifically, no relationship with 






study (20%) than in the general Dutch population (6.5%), although only 1 in 5 was performed 
on maternal cardiac indications.27 Possibly, the threshold for performing caesarean delivery for 
obstetric/offspring reasons is lower than usual because of caution on the part of obstetricians in 
these more vulnerable mothers and babies. The other events were in concordance with expected 
frequencies observed in the general population and mentioned in the literature review.4
Offspring outcome
The high offspring mortality (6.4%) by far exceeds expected mortality rates in the general population 
(0.9%) and also the mortality rate in ToF pregnancies mentioned in the literature (2.0%).28 Recurrence 
of CHD, but also premature births with their known associated events, explains, at least in part, this 
high mortality. The premature birth rate (18%) was substantially higher than expected.4,29 This was in 
part attributable to the higher frequency of PL due to rupture of membranes. The incidence of SGA 
(19%) is also higher than in the general population (by definition 10%), although it is lower than the 
35% recently mentioned by Gelson et al.30 The use of maternal cardiac medication before pregnancy 
was the most important predictor of offspring outcome. Maternal haemodynamic abnormalities as 
well as direct effects of maternal cardiovascular medication may undermine placental blood flow and 
induce placental insufficiency with subsequent intrauterine growth restriction resulting in children 
born SGA as well as in premature birth. The strong association between maternal cardiovascular 
events and SGA points in this direction. Palliative surgery before correction appears to influence 
offspring outcome negatively. Longstanding right ventricular pressure loading and hypoxia in 
women with a later age at correction may have resulted in more haemodynamic compromise and 
endothelial dysfunction, compromising placental perfusion and fetal well being. 
Limitations
The retrospective study design required very strict definitions for events: all mentioned events had to 
be documented by medically qualified personnel in the records according to preset definitions before 
data entry. Heart failure and arrhythmia were only recorded if therapy had been administered. 
This may have caused underestimation of cardiovascular event rate. In addition, selection bias 
is introduced by the fact that some patients remained childless because of anticipated/expected 
risks during pregnancy, which may lead to an underestimation of risks. This study was performed 
in a survival cohort; thus, no conclusions regarding maternal mortality risk can be made. 
However, from prospective research, it is known that repaired CHD has a very low risk of maternal 
death.6,31 Finally, together with the given sample size and the possible effects of multitesting, for 
example, inflation of type I error, all conclusions of the present study must be drawn with caution.
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Aims Data regarding pregnancy outcome in women with congenital heart disease (CHD) 
are limited. 
Methods and results In 1802 women with CHD, 1302 completed pregnancies were observed. 
Independent predictors of cardiac, obstetric, and neonatal complications were calculated using 
logistic regression. The most prevalent cardiac complications during pregnancy were arrhythmias 
(4.7%) and heart failure (1.6%). Factors independently associated with maternal cardiac 
complications were the presence of cyanotic heart disease (corrected/uncorrected) (P<0.0001), the 
use of cardiac medication before pregnancy (P<0.0001), and left heart obstruction (P<0.0001). 
New characteristics were mechanical valve replacement (P=0.0014), and systemic (P=0.04) or 
pulmonary atrioventricular valve regurgitation related with the underlying (moderately) complex 
CHD (P=0.03). A new risk score for cardiac complications is proposed. The most prevalent obstetric 
complications were hypertensive complications (12.2%). No correlation of maternal characteristics 
with adverse obstetric outcome was found. The most prevalent neonatal complications were 
premature birth (12%), small for gestational age (14%), and mortality (4%). Cyanotic heart disease 
(corrected/uncorrected) (P=0.0003), mechanical valve replacement (P=0.03), maternal smoking 
(P=0.007), multiple gestation (P=0.0014), and the use of cardiac medication (P=0.0009) correlated 
with adverse neonatal outcome.
Conclusion In our tertiary CHD cohort, cardiac, obstetric, and neonatal complications were 
frequently encountered, and (new) correlations of maternal baseline data with adverse outcome 




Progress in the fields of diagnostic techniques and surgical intervention has dramatically improved 
long-term outcome in patients with congenital heart disease (CHD). As a consequence, most patients 
with congenital cardiac malformations reach childbearing age. Many of these women wish to become 
pregnant. Pregnancy itself is a circulatory burden, primarily due to volume loading, which has an 
impact even on a healthy woman’s life. In the face of residual lesions or sequelae after correction or 
an uncorrected maternal congenital heart defect, this burden may have deleterious effects on the 
health of both the mother and her offspring. Cardiac, obstetric, and neonatal complications all 
appear to be more prevalent.1 
 It has long been recognized that certain cardiac factors, including prepregnancy NYHA 
class, the presence of a mechanical valve prosthesis, having pulmonary hypertension/cyanosis, 
and outflow tract obstruction, adversely influences pregnancy outcome. The ‘CARdiac disease in 
PREGnancy’ (CARPREG) investigators were the first to identify predictors of the adverse pregnancy 
outcome in women with established heart disease. The investigators also were the first to design a 
risk score, which is now commonly used to ‘predict’ cardiac complications during pregnancy in the 
context of maternal CHD. Limitations of the score for patients with CHD are that it is developed 
based on a cohort that included patients with primary electrical disease as well as acquired heart 
disease. Moreover, several types of (mainly complex) CHD were underrepresented.2,3 It is suggested 
that the CARPREG cardiac risk score therefore needs to be modified to assess the risk of pregnancy 
in women with CHD.4
 The primary objective of the present study is to identify patient characteristics associated 
with adverse pregnancy outcome in a patient cohort consisting of patients with CHD and to propose 
a modified risk score.
Methods
For the present ZAHARA study, female patients with CHD aged 18–58 years enrolled in the 
nation-wide CONgenital CORvitia (CONCOR) registry and a Belgian tertiary medical centre’s 
adult CHD database were identified. The databases include patients with CHD >18 years receiving 
tertiary medical care. The institutional review board or Ethics Committee at each of the seven 
participating tertiary centres approved the protocol. Patients alive at the time of inclusion (survivors) 
were contacted by mail and asked to provide written informed consent. The Ethics Committee 
did not allow review of medical charts without consent. Moreover, we were not allowed to contact 
family members of deceased patients to retrieve informed consent. Therefore, no information on 
excluded or deceased patients is available.
 Data were retrospectively obtained from medical records as reported by qualified medical 
personnel and supplemented data were retrieved by a telephonic questionnaire. The questionnaire 
was mainly used to check data concerning the date of birth/death of offspring, birth weight as 






personnel was consulted to obtain complete data concerning each pregnancy.
 Baseline data including maternal date of birth, parity, age at pregnancy when applicable, 
basic anatomy, prior surgical procedures, co-morbidity, and medical history (using the European 
Paediatric Cardiac Coding) were recorded for all women who gave informed consent. Miscarriages 
and elective abortions were excluded as data concerning these pregnancies are often disputable and 
unreliable. Besides the baseline data, the following complications were recorded for each completed 
(>20 weeks of gestation) pregnancy between 1980 and 2007. Cardiac complications (as diagnosed 
by a tertiary care cardiologist specialist): clinically significant (‘requiring treatment at least 
including drug prescription’) episodes of arrhythmia or heart failure, cardiovascular complications 
(e.a. thrombo-embolic complications, myocardial infarction, and/or cerebrovascular accidents), and 
endocarditis (including first 6 months post-partum). Obstetric complications: pregnancy-induced 
hypertension (PIH, new onset hypertension: blood pressure >140 mmHg systolic or >90 mmHg 
diastolic without proteinuria after 20 weeks of gestation); preeclampsia (PIH with >0.3 g protein 
in 24h urine sample); eclampsia (preeclampsia with grand mal seizures); haemolysis elevated liver 
enzymes low platelets (HELLP) syndrome according to the guidelines of the European Society of 
Gynaecology and Obstetrics premature labour (<37weeks of gestation); post-partum haemorrhage 
(vaginal delivery. 500 mL, caesarean section >1000 mL). Neonatal outcome: premature delivery 
(delivery <37 weeks); small-for-gestational-age birth weight (>10th percentile); offspring mortality 
[demise: in utero (>20 weeks of gestation)—the first-year post-partum].
Data analysis
A Clintrial data-entry program was used to record information and converted to SPSS (version 16.0) 
and SAS for statistical analysis. Descriptive statistics for nominal data were expressed in absolute 
numbers and percentages. Mean values and standard deviations were presented for normally 
distributed continuous variables. For non-normal distributed continuous variables, median and 
ranges were computed. Univariable logistic regression analysis was performed to identify patient 
characteristics associated with adverse pregnancy outcome divided into three composite endpoints 
(as defined above): the cardiac, obstetric complications, and offspring outcome. The following 
baseline variables were assessed: the presence of patent shunt [atrial septal defect, ventricular septal 
defect (VSD), persistent ductus arteriosus, and abnormal pulmonary vein connections], surgical 
status prior to pregnancy (palliation, corrected or uncorrected), history of arrhythmias or cardiac 
complications (heart failure, cerebrovascular accidents, transient ischaemic attack, myocardial 
infarction, thrombo-embolic complications, and endocarditis), left heart obstruction [(i) peak 
aortic gradient >30 mmHg or aortic valve area <1.5 cm2 or mitral valve area <2 cm2 and (ii) peak 
aortic gradient >50 mmHg or aortic valve area <1.0 cm2], right ventricular outflow tract obstruction 
>50 mmHg, reduced systemic ventricular function (qualitative ejection fraction or graded 
quantitative ejection fraction <40% based on echocardiography), presence of cyanosis (oxygen 
saturation <90%) or pulmonary hypertension (systolic pulmonary artery pressure >50 mmHg),2 
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pulmonary valve regurgitation (moderate or severe), systemic valve regurgitation (moderate or 
severe), pulmonary atrioventricular (AV) valve regurgitation (moderate or severe), systemic AV valve 
regurgitation (moderate or severe), aortic dilatation >40 mm (widest diameter), the presence of a 
mechanical valve prosthesis, the presence of a pacemaker, twin pregnancy, cyanotic heart  disease 
(corrected/uncorrected): CHD which presents at or shortly after birth with cyanosis regardless of 
subsequent performed palliative corrective interventions, smoking immediately prior to or during 
pregnancy, alcohol during pregnancy (>0 U/day on average), use of oral anticoagulation and/or 
other cardiovascular medication during pregnancy, and maternal NYHA class prior to pregnancy. 
Variables that were associated with an increased incidence of the studied endpoints (P<0.15) entered 
the multivariable stage. The final multivariable model was then constructed by backward deletion of 
the least significant characteristic, until all remaining variables were significantly (P<0.05) associated 
with the endpoint. Because some women underwent one or more pregnancies, the validity of treating 
each pregnancy as an independent event was determined by general estimating equation analysis.
 For each pregnancy, the now widely used CARPREG cardiac risk score was calculated.2 
We subsequently validated this score for the abovementioned combined endpoint cardiac 
complications. We calculated the C-index (concordance index) of the CARPREG risk score, which 
describes the discriminative capacity, and performed a calibration using the Hosmer–Lemeshow 
test. The C-index has a value between 0.5 (poor discrimination) and 1.0 (perfect discrimination). 
We then modified the CARPREG risk score using the identified multivariable associations for the 
composite cardiac endpoint, nevertheless retaining the basic principal of this risk score.2 In the 
modified risk score, we use the exponent value to weigh the risk factors and attribute points per risk 
factor. The developed risk model based on the whole study cohort was further evaluated by drawing 
1000 bootstrap samples, with replacement, to estimate the extent to which the predictive accuracy 
of the model was overoptimistic. We report the mean C-index and the corresponding standard error 
(SEM).
Results
Overall, 1802 women with CHD (82%) provided written informed consent to review their medical 
records. These patients had 1696 gestations, including 336 miscarriages (19.4%; <20 weeks of 
gestation) and 58 elective abortions (3.4%). For the present analyses, the data of the 1302 completed 
pregnancies in 714 individual women were used. Most patients were nulliparous (63%). Mean 
maternal age at pregnancy was 27.4 (SD±2.6) years. The underlying CHD in the women with 
completed (>20 weeks of gestation) pregnancies in detail: (un)-corrected atrial septal defect II (n=188), 
(un)-corrected aortic coarctation including additional cardiac defects (n=160), (un)-corrected VSDs 
(n=148), pulmonary valve stenosis (n=148; including 21 with >50 mmHg obstruction), corrected 
tetralogy of Fallot (n=124), Marfan syndrome (n=18; including 32 with aortic root dilatation >40 
mm), atrioventricular septal defect (n=89, of which 15 with common orifice), aortic valvar stenosis 






of great arteries (TGA) (n=52, mostly Mustard corrections), (un)-corrected Ebstein malformations 
(n=22), congenital corrected TGA (n=19), pulmonary atresia with VSD (n=12), Eisenmenger 
syndrome (n=4), complex cyanotic heart disease (n=9, including patients with Fontan palliation), 
and other CHD [n=128, including isolated mitral/tricuspid valvular regurgitation (respectively, 
n=30 and n=1)]. The distribution of complications encountered during these completed (>20 weeks 
of gestation) pregnancies is illustrated in Table 1. It needs to be stated that, in part, these results are 
published in the earlier work by our research group and are merely shown for illustrative purposes.5-14 
Main cardiac complications were arrhythmias (4.7%) and heart failure (1.6%), mostly transient in 
nature and manageable with medical therapy. 
Table 1. Complications found during 1302 completed pregnancies organized per category  










AR HF CE EN PI PE EC HE PL PH PD SG MO
Atrial septal defect 188 7 0 2 0 9 12 0 0 12 19 12 33 4
Aortic coarctation 160 2 1 0 1 8 7 0 0 8 19 22 18 6
Ventricular septal 
defect
148 1 0 1 1 8 9 0 0 7 16 6 16 1
Pulmonary valve 
stenosis
148 3 1 3 0 12 7 2 1 5 16 20 15 7
Tetralogy of Fallot 124 7 1 1 0 5 4 0 0 9 12 21 20 7
Marfan syndrome 118 1 0 2 0 13 1 0 0 5 11 16 14 8
Atrioventricular septal 
defects
89 15 3 2 0 9 2 0 0 6 12 10 15 4
Aortic valvar stenosis 81 3 4 0 0 10 3 1 1 5 5 10 9 1
Complete transposition 
of the great arteries
52 11 4 2 0 7 5 0 1 6 7 16 10 5
Ebstein malformation 22 2 0 1 0 0 0 0 0 0 4 2 1 1
Congenital corrected 
transposition of great 
arteries
19 1 2 0 0 2 0 0 2 1 1 1 3 0
Pulmonary atresia 12 3 0 0 0 0 0 1 1 0 0 1 1 0
Pulmonary hyperten-
sion or Eisenmengera
4 0 1 0 0 0 0 0 0 0 0 2 0 0
Complex cyanotic 
heart disease
9 3 2 0 0 1 0 0 0 1 2 6 5 1
Other 128 3 2 0 0 1 0 0 0 1 2 6 5 1
Overall 1302 62 21 17 2 94 57 4 6 76 139 160 180 49
N, number of pregnancies. AR, arrhythmias; HF, heart failure; CE, cardiovascular complications; EN, endocarditis; 
PI, pregnancy-induced hypertension; PE, preeclampsia; EC, eclampsia; HE, HELLP syndrome; PL, premature labour; 
PH, post-partum haemorrhage; PD, premature delivery; SG, small for gestational age; MO, foetal or neonatal mortality. 
a Respectively, ASD related n=2 and VSD related n=2.
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The most important obstetric complications were hypertension-related disorders (mainly occurring 
in uncorrected patients). The most frequently encountered offspring outcomes were born small for 
gestational age and premature delivery. Maternal cardiac complications and offspring complications 
were highly correlated (r=0.85, P=0.002). 
 The results of the univariable logistic regression are shown in Table 2. 








Patent shunt 0.6 (0.3 – 1.0) 1.0 (0.7 – 1.3) 0.7 (0.5 – 1.0)
Only palliation before pregnancy 9.8 (2.8 – 34.1)*** 1.7 (0.4 – 7.1) 2.7 (0.7 – 10.9)
Corrected before pregnancy 1.6 (1.0 – 2.7) 1.0 (0.8 – 1.4) 1.3 (1.0 – 1.7)
History of arrhythmias 5.0 (2.3 – 11.0)*** 0.9 (0.3 – 2.3) 1.2 (0.6 – 2.6)
History of cardiac complications 1.5 (0.4 – 5.0) 1.0 (0.4 – 2.3) 2.2 (1.0 – 4.7)*
LHO (PG >30mmHg or AVA <1.5 cm2) 
+ mitral valve stenosis (MVA <2.0 cm2)a
2.6 (1.2 – 5.5)* 1.0 (0.5 – 1.8) 0.5 (0.3 – 0.9)*
LHO (PG >50 mmHg or AVA <1.0 cm2) 7.4 (2.6 – 21.2)*** 0.4 (0.1 – 1.5) 0.6 (0.2 – 1.6)
Pulmonary ventricular outflow obstruction 
(PG >50 mmHg)
2.2 (0.9 – 5.7) 1.4 (0.7 – 2.5) 1.2 (0.7 – 2.1)
Reduced systemic ventricular function 3.3 (1.3 – 8.3)** 0.5 (0.2 – 1.2) 1.6 (0.7 – 3.7)
Cyanosis or pulmonary hypertension 1.9 (0.3 – 12.9) 0.6 (0.1 – 3.9) 3.2 (0.8 – 12.9)
Pulmonary valve regurgitationb 1.5 (0.7 – 3.5) 1.2 (0.8 – 2.0) 0.9 (0.5 – 1.4)
Systemic valve regurgitationb 1.1 (0.4 – 2.9) 1.0 (0.5 – 1.7) 0.8 (0.4 – 1.5)
Systemic AV valve regurgitationb 2.7 (1.4 – 5.2)** 0.9 (0.6 – 1.5) 1.4 (0.8 – 2.2)
Pulmonary AV valve regurgitationb 2.9 (1.6 – 5.4)*** 0.8 (0.5 – 1.3) 1.4 (0.8 – 2.1)
Aortic dilatation (>40 mm) 1.7 (0.7 – 4.5) 0.8 (0.4 – 1.7) 0.8 (0.4 – 1.6)
Mechanical prosthesis 37.1 (3.8 – 360.8)** 9.3 (1.0 – 90.1) 9.0 (0.9 – 87.3)
Pacemaker 4.6 (1.8 – 11.5)** 2.7 (1.1 – 6.6)** 0.5 (0.2 – 1.5)
Twin or multiple gestation 2.0 (0.6 – 7.0) 2.3 (1.0 – 5.9) 6.4 (2.3 – 17.8)***
Cyanotic heart disease 
(corrected and uncorrected)
2.8 (1.7 – 4.7)*** 0.9 (0.6 – 1.3) 2.0 (1.4 – 2.9)***
Smoking before pregnancy 0.9 (0.5 – 1.5) 0.9 (0.6 – 1.2) 1.4 (1.0 – 1.9)
Smoking during pregnancy 1.1 (0.6 – 2.0) 0.7 (0.4 – 1.0) 1.6 (1.1 – 2.3)**
Alcohol during pregnancy 1.2 (0.6 – 2.6) 1.2 (0.7 – 2.0) 0.7 (0.4 – 1.2)
Oral anticoagulation 5.7 (2.4 – 13.5)*** 1.9 (0.8 – 4.7) 2.7 (1.0 – 7.2)
Other cardiac medication before pregnancy 4.2 (2.3 – 7.8)*** 1.0 (0.6 – 1.8) 2.1 (1.4 – 3.3)***
NYHA 3.1 (1.6 – 6.0)*** 0.8 (0.4 – 1.4) 1.1 (0.7 – 1.8)
AV, atrioventricular; AVA, aortic valve area; LHO, left heart obstruction; MVA, mitral valve area; NYHA, New York Heart 
Association; PG, peak gradient. Values are expressed as odds ratio (95% Confidence Interval).
a None of the patients had a MVA of <2.0 cm2.
b Moderate/severe.






The event rate per characteristic is reported in Table 3. 
Table 3. Event rate per characteristics in absolute numbers (percentages) for the three composite 











Overall 1302  99 (7.6)  313 (24.0)  331 (25.4)
Patent shunt 306  14 (4.6)  72 (23.5)  65 (21.2)
Only palliation before pregnancy 9  4 (44.4)  3 (33.3)  4 (44.4)
Corrected before pregnancy 683  65 (9.5)  166 (24.3)  189 (27.7)
History of arrhythmias 39  12 (30.8)  9 (23.1)  12 (30.8)
History of cardiac complications 33  3 (9.1)  7 (21.2)  13 (39.4)
LHO (PG >30 mmHg or AVA <1.5 cm2)  
+ mitral valve stenosis (MVA < 2.0 cm2)a
71  11 (15.5)  16 (22.5)  11 (15.5)
LHO (PG >50 mmHg or AVA <1.0 cm2) 22  7 (31.8)  2 (9.1)  4 (18.2)
Pulmonary ventricular outflow obstruction 
(PG >50 mmHg)
68  10 (14.7)  21 (30.9)  20 (29.4)
Established reduced systemic  
ventricular function
35  7 (20.0)  5 (14.3)  14 (40.0)
Cyanosis or pulmonary hypertension 9  1 (11.1)  1 (11.1)  5 (55.6)
Pulmonary valve regurgitationb 109  11 (10.1)  29 (26.6)  24 (22.0)
Systemic valve regurgitationb 76  6 (7.9)  16 (21.1)  16 (21.1)
Systemic AV valve regurgitationb 106  17 (16.0)  24 (22.6)  34 (32.1)
Pulmonary AV valve regurgitationb 105  18 (17.1)  21 (20.0)  33 (31.4)
Aortic dilatation (>40 mm) 58  6 (10.3)  13 (22.4)  12 (20.7)
Mechanical prosthesis 4  4 (100.0)  3 (75.0)  3 (75.0)
Pacemaker 29  8 (27.6)  14 (48.3)  4 (13.8)
Twin or multiple gestation 17  2 (11.8)  7 (41.2)  11 (64.7)
Cyanotic heart disease 
(corrected and uncorrected)
198  31 (15.7)  45 (22.7)  75 (37.9)
Smoking before pregnancy 313  21 (6.7)  70 (22.4)  96 (30.7)
Smoking during pregnancy 192  14 (7.3)  34 (17.7)  66 (34.4)
Alcohol during pregnancy 89  7 (7.9)  22 (24.7)  16 (18.0)
Oral anticoagulation 24  10 (41.7)  10 (41.7)  12 (50.0)
Other cardiac medication before pregnancy 96  21 (26.2)  21 (26.2)  34 (42.5)
AV, atrioventricular; AVA, aortic valve area; LHO, left heart obstruction; MVA, mitral valve area; NYHA, New York Heart 
Association; PG, peak gradient.
a None of the patients had a MVA of <2.0 cm2.
b Moderate/severe.
The bold entries are the statistical significant data, which makes interpretation simpler.
The multivariate model correlating the composite endpoints of cardiac and neonatal complications 
is shown in Table 4. New independent (multivariable) factors associated with cardiac complications 
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were the presence of a moderate-to-severe pulmonary or systemic AV valve regurgitation, cyanotic 
heart disease (corrected/uncorrected), and the presence of mechanical valve prosthesis. A history 
of arrhythmias, maternal NYHA functional class, the presence of left ventricular outflow tract 
obstruction, and the use of cardiac drugs also proved to be independent predictors of cardiac 
complications in concordance with previous studies.
Table 4. Multivariable model for the composite endpoints of cardiac and neonatal complications 
corrected for maternal age and parity.
Odds ratio (95% CI) P value
CARDIAC COMPLICATIONS
History of arrhythmias  4.3 (1.8 – 10.2)  0.0011
Other cardiac medication before pregnancy  4.2 (2.1 – 8.6)  <0.0001
NYHA functional class  2.2 (1.1 – 4.5)  0.0298
LHO (PG >50 mmHg or AVA <1.0 cm2)  12.9 (3.9 – 42.3)  <0.0001
Syst AV valve regurgitation (moderate/ severe)  2.0 (1.0 – 4.0)  0.0427
Pulm AV valve regurgitation (moderate/ severe)  2.3 (1.1 – 5.0)  0.0287
Mechanical valve prosthesis  74.7 (5.3 – 1057)  0.0014
Cyanotic heart disease (corrected and uncorrected)  3.0 (1.7 – 5.0)  <0.0001
NEONATAL COMPLICATIONS
Twin or multiple gestation  5.4 (1.9 – 15.2)  0.0014
Smoking during pregnancy  1.7 (1.2 – 2.4)  0.0070
Cyanotic heart disease (corrected and uncorrected)  2.0 (1.4 – 2.9)  0.0003
Mechanical valve prosthesis  13.9 (1.2 – 157)  0.0331
Other cardiac medication before pregnancy  2.2 (1.4– 3.5)  0.0009
AV, atrioventricular; AVA, aortic valve area; LHO, left heart obstruction; NYHA, New York Heart Association; PG, peak gradient; 
Pulm, pulmonary; Syst, systemic. 
None of the investigated patient characteristics were associated with adverse obstetric complications. 
The presence of multiple gestations, the presence of at birth cyanotic heart disease, the presence of 
mechanical valve prosthesis, smoking during pregnancy, and the use of cardiac medication other 
than anticoagulation regimes were independently associated with adverse neonatal complications. 
In Table 5, the details regarding the encountered cardiac complications are described, including 
the underlying CHD. The performance of the CARPREG cardiac risk score was limited with a 
C-index of 0.656 for the composite cardiac endpoint. Figure 1 shows the alternative risk score and 
the corresponding cardiac risk during pregnancy. The mean C-index of this risk model, as obtained 
in the 1000 bootstrap samples, was 0.762 with a SEM of 0.026. This implies some over-optimism in 
the estimated predictive accuracy of the model. In the future, this new cardiac risk index needs to 







The present, and thus far largest, study investigates the pregnancy complications in women with 
CHD. Complications were frequently encountered. Several new associations with adverse cardiac 
and neonatal pregnancy complications were identified. On the basis of these associations, a new 
risk index was designed, which seems to enhance discrimination and calibration compared with the 
existing CARPREG risk score. External validation of this risk score in a large prospective study, 
however, remains necessary.
Predicting cardiac complications
In our study, cardiac complications occurred during 7.6% of completed pregnancies, slightly lower 
than the 11% reported in our recent review.1 Clinically significant episodes of arrhythmias (4.7%) 
and heart failure (1.6%) were the most important of cardiac complications. The lower prevalence of 
cardiac complications was largely attributable to the lower incidence of heart failure (1.6 vs. 4.8%).1 
As heart  failure is difficult to distinguish from ‘normal’ physiological developments associated with 
pregnancy, including malleolar edema, shortness of breath during exercise, and increased nocturnal 
urination frequency, we used a strict definition. The occurrences of other cardiac complications were 
in line with expectations.
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Table 5. Presence of predictors and the number of complications encountered in these patients.
Risk factor      N Cardiac complications
Underlying CHD in pregnancies 
with complications
History of arrhythmias 39
AR (n= 8); HF (n= 1); 
CE (n= 3); EN (n= 0)
TGA 3; ASD 2; ccTGA 1; AOS 1; 
TOF 1; VSD 1; AVSD 1; PS 1; UVH 1.
Other cardiac medication before 
pregnancy
80
AR (n= 16); HF (n= 4); 
CE (n= 4); EN (n= 0)
TGA 6; AVSD 5; TOF 3; Marfan 2; 
MR 1, AOR 1; VSD 1; ASD 1.
NYHA functional class 7
AR (n= 1); HF (n= 1); 
CE (n= 0); EN (n= 0)
PAVSD 1; AOR 1.
LHO (PG >50 mmHg or AVA <1.0 cm2) 22
AR (n= 2); HF (n= 2); 
CE (n= 0); EN (n= 0)
AOS 5; AVSD 1; CoA 1
Syst AV valve regurgitationd 106
AR (n= 7); HF (n= 8); 
CE (n= 1); EN (n= 0)
AVSD 9; TGA 3;ccTGA 1;MVP 1; AOS 1; 
Eisenmenger 1.
Pulm AV valve regurgitationd 105
AR (n= 10); HF (n= 3); 
CE (n= 2); EN (n= 1)
AVSD 6; Ebstein 3; PAVSD 3; DORV 1; 
TOF 1; VSD 1; Eisenmenger 1.
Mechanical valve prosthesisa 6
AR (n= 3); HF (n= 2); 
CE (n= 2)*; EN (n= 0)
AOS 3; AOR 1; MR 2
Cyanotic heart disease 
(corrected and uncorrected)
198
AR (n= 24); HF (n= 8); 
CE (n= 3); EN (n= 0)
TGA 13; TOF 9; PAVSD 3; UVH 3;  
DORV 1; AOS 1;Eisenmenger 1.
Neonatal complications
Twin or multiple gestation 18
PD (n= 10); SG (n= 4); 
MO (n= 1)
Smoking during pregnancy 192
PD (n= 28); SG (n= 40); 
MO (n= 8)
Cyanotic heart disease (corrected and 
uncorrected)
198
PD (n= 46); SG (n= 34); 
MO (n= 13)
Mechanical valve prosthesisc 6
PD (n= 3); SG (n= 1); 
MO (n= 0)
Other cardiac medication before 
pregnancy
80
PD (n= 22); SG (n= 14); 
MO (n= 7)
AOR, aortic valve regurgitation; AOS, aortic valve stenosis; AR, arrhythmias; ASD, atrial septal defect; AV, atrioventricular; 
AVA, aortic valve area; AVSD, atrioventricular septal defect; ccTGA, congenital corrected transposition of great arteries; 
CE, cardiovascular complications; CoA, aortic coarctation; DORV, double outlet right ventricle; EN, endocarditis; HF, heart 
failure; LH, left heart; Marfan, Marfan syndrome; MO, foetal or neonatal mortality; MR, isolated mitral valve regurgitation; 
MVP, mitral valve prolaps; NYHA, New York Heart Association; PAVSD, pulmonary atresia with VSD; PD, premature delivery; 
PG, peak gradient; PS, pulmonary valve stenosis; Pulm, pulmonary; SG, small for gestational age; Syst, systemic; TGA, atrial 
complete transposition of great arteries; TOF, Tetralogy of Fallot; UVH, univentricular heart; VSD, ventricular septal defect. 
a Position of mechanical valve: 4 aortic, 2 mitral; type of mechanical valve: all bileaflet, except 1 Björk-Shiley mitral valve. 
b Both cardiovascular complications were mechanical valve thrombosis occurring at 12 and 14 weeks of gestation shortly 
after switch of full dose subcutaneous low molecular weight heparin back to oral anticoagulation (one aortic bileaflet 
prosthesis; one Björk shiley mitral valve prosthesis). No other risk factors for thrombotic complications were present during 
these pregnancies. One of these patients had two additional episodes of thrombosis during the same pregnancy, which 
were not analysed separately.







Figure 1. The modified risk score for cardiac complications during completed (>20 weeks of gestation) 
pregnancies in women with congenital heart disease (expressed as % of the total number of completed 
pregnancies). AV, atrioventricular; AVA, aortic valve area; LHO, left heart obstruction; NYHA, New York 
Heart Association; PG, peak gradient; Pulm, pulmonary; Syst, systemic.
New associations with adverse cardiac complications were: (i) the presence of moderate/severe 
systemic or pulmonary AV valve regurgitation, (ii) the presence of mechanical valve prosthesis, and 
(iii) ‘at birth’ cyanotic CHD. (i) The presence of significant AV valve regurgitation is known to cause 
volume loading and atrial distension. These factors are subsequently linked with the development 
of heart failure and supraventricular arrhythmias. In patients with significant pulmonary AV 
valve regurgitation, the majority of complications were arrhythmias. The vulnerability to develop 
arrhythmias is a well-known long-term complication in these patients even outside pregnancy. Up 
till now, due to the decrease in systemic vascular resistance, the importance of systemic AV valve 
regurgitation during pregnancy was thought to be limited. Therefore, our finding that moderate/
severe systemic AV valve regurgitation independently predicts maternal complications is important, 
in particular as half of the complications consisted of heart failure. Importantly, we need to 
realize that in a significant proportion of patients, the moderate-to-severe AV valve regurgitation 
was associated with (moderately) complex CHD, and concomitant ventricular dysfunction and/
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or dilatation may have been involved in the development of complications. This risk factor should 
therefore be interpreted in the context of the associated heart disease and ventricular function. (ii) 
The fact that the presence of a mechanical valve correlated with adverse cardiac outcome is not 
surprising. Several case series and reports have described important cardiac complications including 
maternal mortality, heart failure, arrhythmias, and mechanical valve thrombosis.15-17 Especially, 
although not exclusively, patients with old generation valves in mitral valve position appeared at 
greater risk for valve thrombosis.15 In all our patients with mechanical valves, cardiac complications 
occurred (Table 4), including mechanical valve thrombosis during two pregnancies, one in a woman 
with a high-risk mechanical prosthesis (mitral Björk Shiley) but the other in a woman with a bileaflet 
aortic valve. Both events presented shortly after switching therapy from subcutaneous full fixed 
dose low molecular weight heparin to oral anticoagulation consisting of acenocoumarol. At present, 
the anticoagulation regime best used during pregnancy in women with mechanical valves is still a 
subject of debate. The used schedule is not advocated in the official ESC guideline.18 Moreover, in 
our patients, anti-factor Χa levels were not monitored; this may well have negatively affected the 
occurrence of valve thrombosis. (iii) The fact that patients with at birth cyanotic heart disease appear 
to be at greater risk for cardiac complications most likely reflects the complexity of the underlying 
heart condition. Patients with more complex heart disease need more interventions and are more 
prone to develop complications outside pregnancy.19 The burden of pregnancy may accelerate the 
development of adverse cardiac complications.
 In concordance with the CARPREG and other investigators, we identified NYHA functional 
class >II, left heart obstructive lesions, and a history of arrhythmias to be independent predictors of 
maternal cardiac complications.20,21 It needs to be added that arrhythmias were the most common 
cardiac complication in women with a history of arrhythmias. Silversides et al.22 reported earlier that 
in women with pre-existing cardiac rhythm disorders, exacerbation of arrhythmic episodes during 
pregnancy was common.
 In contrast to the CARPREG report, a decreased systemic ventricular function was 
a univariate but not multivariate predictor of cardiac complications. In this retrospective study, 
we had to use a less accurate definition for decreased left ventricular function (subjective mostly 
echocardiographic estimation vs. measurement of ejection fraction in the CARPREG study) 
which may in part explain this difference. The association between significant systemic AV valve 
regurgitation and decreased systemic ventricular function (e.g. in patients with a systemic right 
ventricle) may be another part of the explanation, as systemic AV valve regurgitation emerged as an 
independently associated characteristic in our study. Cyanosis and a history of cardiac complications 
also did not correlate with adverse cardiac outcome. The low incidence of these variables may at least 
be in part the explanation. Cyanotic women are often advised against pregnancy.23
Predicting obstetric complications






disorders of pregnancy were the most important obstetric complication occurring in 12.2% 
(including preeclampsia in 4.4%). No plausible associations with adverse obstetric outcome were 
found.
Predicting neonatal complications
Neonatal complications were premature birth (12%), small for gestational age (14%), and mortality 
(4%), overall complicating 25% of completed pregnancies. In comparison with the results summarized 
in our literature review, the occurrence of small for gestational age and offspring mortality is higher, 
which could be mainly attributed to the relatively higher percentage of complex CHD.
 New associations were the use of cardiac medication, ‘at birth’ cyanotic heart disease, and 
mechanical valve prosthesis. The fact that at birth cyanotic heart disease and the use of cardiac 
medication predicted neonatal complications most probably reflects the severity of the underlying 
heart disease. Mechanical valve prosthesis mainly resulted in premature delivery which may be the 
result of precautions taken by the attending physician as most deliveries were induced prematurely 
(possibly because of maternal cardiac complications). In several case series, similar observations were 
done.16,17
 In the CARPREG study, predictors for neonatal complications were NYHA functional class 
or cyanosis, left heart obstructive lesions, smoking during pregnancy, multiple gestations, and the 
use of anticoagulation during pregnancy. In our population, the maternal functional class >II or 
cyanosis did not appear to be a risk factor, probably at least in part due to the low prevalence 
in our population. Also patients with left heart obstruction did not appear to be at greater risk 
for offspring complications. In correspondence with the report by Siu et al., in our study, women 
with a twin gestation and those who smoke during pregnancy were at a higher risk for offspring 
complications (Table 5). The most important risk associated with multiple gestations is spontaneous 
preterm delivery, which is subsequently related with increased perinatal mortality and morbidity.24,25 
Smoking during pregnancy is also a well-known risk factor that affects neonatal outcome.26
Risk scores
The CARPREG risk score performed inadequately in our population and largely overestimated 
risk, in line with other reports.27,28 The differences between the populations that we pointed out 
may in part explain the poor performance of the CARPREG cardiac risk score in our population. 
In addition, the incidence of cardiac complications appears relatively low (7.6%) in comparison to 
13 and 19.4% reported by Siu et al.2,3,29 and Khairy et al.4 However, the cardiac complication rate in 
the CARPREG study in patients with CHD is 7.1% (32 in 445 pregnancies). Apparently, acquired 
or arrhythmic heart disease patients are at higher risk. The cohort investigated by Khairy et al. had 
an overrepresentation of complex CHD, which may explain the higher cardiac complication rate. 
Nonetheless, the different definition of heart failure (therapeutic interventions had to be performed) 
that we needed to use in this retrospective study could also in part explain this discrepancy. The 
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incidence of cardiac complications in our study, however, is comparable to the frequency found 
in a recently published literature review.1 The modification of the risk index (as explained in the 
Results section) seems to enhance discrimination and calibration. Importantly, both risk scores 
have significant limitations restricting indiscriminative use. The representation of risk factors in the 
population determines which risk factors emerge. Important risk factors such as pulmonary arterial 
hypertension are likely to be underrepresented in contemporaneous cohorts, preventing such risk 
factors to be identified. Therefore, it is important to underline that the calculation of risk scores 
should be only a part of prepregnancy risk assessment. We advocate a prepregnancy evaluation in an 
outpatient setting, including physical examination, laboratory evaluation, and an echocardiography 
according to a predefined protocol by an expert in the field. In addition to weighing predictors 
found in ZAHARA and CARPREG and calculating risk scores, disease-specific information should 
always be used when estimating pregnancy risk in order to avoid over-simplification implied by risk 
calculation. Also existing guidelines and expert articles should be consulted.30 External validation 
of our modified risk score in a large prospective study remains necessary, before use in everyday 
practice is possible.
Limitations
Most of the limitations of the present study are related to the retrospective design. First and most 
importantly, the present study lacks a historical ‘matching’ control population. This is, however, not 
as straightforward and simple exercise, as the vast majority of healthy women in the Netherlands and 
Belgium deliver at home with the help of a midwife. Therefore, the women consulting gynecological 
hospital care are a selected population with (mainly obstetric or neonatal) complications or at higher 
risk for these complications. Moreover, the concept of a control population is, in our opinion, 
only sustainable, when both cohorts are followed in an identical fashion according to a predefined 
protocol. Therefore, a prospective study would be the best option, on the other hand, to collect 
the number of pregnancies provided in the present study; data collection would take at least 10 
years and interfere with the contemporaneous applicability. A second limitation is the possibility 
of underreporting. Because data-retrieval was retrospective, only documented complications (by 
medically educated personnel) were included. Third, we need to take into account that for the 
present study, a survivor cohort was selected, therefore not allowing the investigation of maternal 
mortality. Moreover, patients thought to be at high risk based on earlier studies, e.g. Eisenmenger 
syndrome and many Fontan patients, are generally advised against pregnancy or mainly patients at 
relatively good health achieve pregnancy. The risk of pregnancy in women with these complex heart 
diseases can therefore be underestimated in this study; nevertheless, it represents today’s policies 
regarding pregnancy. Another limitation concerns the impossibility in this retrospective study 
to accurately quantify the severity of systemic and pulmonary ventricular volumes and function. 
Also the exclusion of miscarriage and abortion pregnancies may result in an underestimation of 






supraventricular arrhythmia with secondary heart failure. To include these pregnancies in the 
analyses would, however, lead to an underestimation of other complications that incorporated a 
certain gestational age to develop, i.e. hypertensive disorders. Moreover, the limitations associated 
with the low-risk contrast, the still relatively small cohort, and the lower incidence of complications 
and subsequent impossible internal validation need to be taken into account. The present cohort 
is representative for a CHD population receiving tertiary medical care, including patients with 
complex heart disease; caution, however, is needed when extrapolating the results to populations 
with another CHD distribution. In summary, the results should be interpreted with caution.
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Background Previous research has shown that women with congenital heart disease (CHD) are 
more susceptible to cardiovascular, obstetric, and offspring events. The causative pathophysiologic 
mechanisms are incompletely understood. Inadequate uteroplacental circulation is an important 
denominator in adverse obstetric events and offspring outcome. The relation between cardiac 
function and uteroplacental perfusion has not been investigated in women with CHD. Moreover, 
the effects of physiologic changes on pregnancy-related events are unknown. In addition, long-term 
effects of pregnancy on cardiac function and exercise capacity are scarce.
Methods Zwangerschap bij Aangeboren Hartafwijking (ZAHARA) II, a prospective multicenter 
cohort study, investigates changes in and relations between cardiovascular parameters and 
uteroplacental Doppler flow patterns during pregnancy in women with CHD compared to matched 
healthy controls. The relation between cardiovascular parameters and uteroplacental Doppler flow 
patterns and the occurrence of cardiac, obstetric, and offspring events will be investigated. At 20 and 
32 weeks of gestation, clinical, neurohumoral, and echocardiographic evaluation and fetal growth 
together with Doppler flow measurements in fetal and maternal circulation are performed. Maternal 
evaluation is repeated 1 year postpartum.
Implications By identifying the factors responsible for pregnancy-related events in women with 
CHD, risk stratification can be refined, which may lead to better prepregnancy counseling and 
eventually improve treatment of these women.
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Background
Because of improved long-term survival, most women with congenital heart disease (CHD) reach 
child-bearing age and many pursue pregnancy. In women with uncorrected maternal congenital 
heart defects or with residual sequelae after correction, the haemodynamic changes in pregnancy 
can have negative effects on the health of both mother and her (unborn) child. Cardiac events are 
rare in healthy women (<1%), while arrhythmias occur in 4.5% and heart failure in 4.8% of women 
with CHD.1 In complex CHD, cardiac event rate can be even higher.1-4 Women with CHD are not 
only more susceptible to cardiac events, but obstetric and offspring events are also more prevalent.1-3 
Important obstetric events are postpartum hemorrhage (8%, up to 29%), pregnancy-induced 
hypertension (5.5%, up to 13%), preeclampsia (PE; 3.2%, up to 10%), and preterm delivery (16%, 
up to 65%); whereas in healthy pregnant women, the prevalence of these events is much lower.1 
Frequently observed events in offspring of women with CHD are intrauterine growth restriction 
(IUGR), prematurity, and mortality.1-3 The magnitude of these risks depends, at least in part, on the 
type and severity of maternal CHD. In the general population, both IUGR and PE are associated 
with a lower cardiac output (CO), an elevated total vascular resistance (TVR), and abnormal uterine 
and umbilical artery Doppler waveform patterns.5,6 These parameters can be used to identify women 
at risk for PE and IUGR. The higher incidence of these events in women with CHD may be caused 
by inadequate maternal haemodynamics, resulting in insufficient uteroplacental circulation.7,8 
Nevertheless, the interaction between echocardiographic, haemodynamic, and neurohumoral 
parameters on one side and uteroplacental Doppler flow patterns on the other side in relation to 
pregnancy outcome have not been studied in women with CHD and have not been compared 
to those in healthy pregnant women. In addition, although some studies identified predictors of 
cardiac events in women with both acquired and CHD, prospective data relating echocardiographic 
parameters of ventricular or valvular function to maternal cardiac events are still scarce and little is 
known about the long-term effects of pregnancy on cardiac function or exercise capacity in women 
with CHD.2,3,9 The mid- and longterm effects of pregnancy on cardiovascular haemodynamics have 
been described in a few select subgroups.10,11 In these studies, however, exercise capacity or cardiac 
biomarkers were not assessed. In this article, we will introduce the study design and describe the 
rationale of the ZAHARA II study.  
Methods
Study objectives
The primary objective of the present study is to compare cardiovascular, neurohumoral, and 
uteroplacental Doppler flow changes during pregnancies of women with CHD with age- and 
parity-matched healthy controls and to relate these changes to the occurrence of cardiovascular and 
obstetric events and to offspring outcome. The secondary objective of this study is to evaluate the 







This is an observational prospective multicenter cohort study.
Study population
Women with any morphological CHD with a pregnancy of <20 weeks duration, presenting in the 
participating centers, who meet all the inclusion and none of the exclusion criteria are eligible (Table 1). 
During a 3-year period, a minimum of 160 women with CHD are enrolled, and simultaneously, 
60 healthy, age- and parity-matched women are recruited from a low-risk midwife practice in 
Groningen and in Rotterdam, the Netherlands, to serve as controls. We will use a subclassification 
for our cohort where appropriate, using division in disease complexity, the adapted World Health 
Organization classification for estimating pregnancy risk, or clustering of the morphological and 
functional comparable diseases as in previous studies.2,9,12,13
Table 1. Inclusion and exclusion criteria of ZAHARA II
Women WITH CHD
Inclusion criteria
 Age ≥18 y
 Morphological CHD
 Presentation at ≤20 wk of gestation
 Presentation in one of the participating medical centers
exclusion criteria
 Miscarriage or termination of pregnancy <20 wk of gestation
 Alcohol abuse
 Illicit drugs use
HeAlTHy ConTRols
Inclusion criteria
 Age ≥18 y
 Presentation at ≤20 wk of gestation
exclusion criteria
 Miscarriage or termination of pregnancy <20 wk of gestation
 Women who are on chronic medication
 Women who are under specialist control
 Alcohol abuse
 Illicit drugs use
Measurements
Baseline data are recorded at the first prenatal visit using medical records and include underlying 
heart disease, prior interventions, cardiac sequelae, prior cardiac events, comorbidity, and obstetric 
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history. Maternal age, parity, present cardiac status (including New York Heart Association 
functional class, physical examination, oxygen saturation, and echocardiographic data), use of 
medication, intoxications, educational status, and current employment are also recorded. Clinical 
evaluation at gestational weeks 20 and 32 as well as at 1 year postpartum is performed for follow-
up data and for registration of events. During follow-up echocardiograms, electrocardiograms and 




Standardized echocardiograms according to disease-specific protocols are performed at 20 and 
32 weeks of gestation and at 1 year postpartum. Echocardiograms are evaluated off-line in the 
University Medical Center Groningen, Groningen, the Netherlands. Morphological left and right 
ventricular size and function (if feasible, ejection fraction according to Simpson’s rule), atrial size, 
valvular function (quantification of regurgitation and stenosis of all valves) as well as disease-specific 
evaluation (i.e., presence and location of intracardiac shunts, evaluation of conduits, or baffles) are 
performed according to current recommendations and guidelines.14-20 Blood pressure and heart 
rate are measured during echocardiography to calculate CO and TVR as described previously.15,17,19 
Prepregnancy routinely performed echocardiograms (available in most of the patients) are analyzed 
for comparison.
Obstetric evaluation 
Fetal biometry is assessed by ultrasound and uteroplacental perfusion is studied by Doppler flow 
measurements of uterine arteries. Umbilical artery pulsatility index, resistance index, and uterine 
artery flow and early diastolic notching are evaluated at 20 and 32 weeks of pregnancy according to 
the guidelines of the International Perinatal Doppler Society.5,21 Evaluation of the digitally stored 
(Doppler) ultrasound registrations is performed in the University Medical Center Groningen. 
Blood and urinalysis
Haematologic parameters, renal and hepatic function, haemoglobin A1c as well as nonfasting 
glucose, and N-terminal prohormone brain natriuretic peptide (NT-proBNP) are assessed from 
blood samples at 20 and 32 weeks of gestation and 1 year postpartum and compared with the values 
before pregnancy, if available. Proteinuria is quantitatively assessed at 20 and 32 weeks of gestation. 
Cardiopulmonary aerobic capacity testing
Cardiopulmonary aerobic capacity testing is performed 1 year postpartum in patients who 







Clinical adverse events in ZAHARA II are subdivided in cardiac, obstetric, offspring, and general adverse 
events (Table 2). We define cardiovascular events as described in previous studies (Table 2). In addition, we 
assess changes in NT-proBNP levels and in echocardiographic findings in patients with CHD compared 
to those in healthy controls. We define abnormal echocardiographic changes in pregnancies as a significant 
deterioration in size or function of subpulmonary or sub-aortic ventricle; new onset or aggravation of 
valve regurgitation ≥1 grade (mild to moderate or severe, or moderate to severe) during pregnancy and/or 
persisting 1 year postpartum; persistent (≥1 year) significant aggravation of valve stenosis (mild to moderate 
or severe, or moderate to severe); significant increase in aortic dimensions (≥5 mm) during pregnancy 
and/or 1 year postpartum. Furthermore, pulsatility index >95th centile in umbilical artery, uterine artery 
resistance index >95th centile, umbilical artery resistance index >0.58 or >90th centile, or early diastolic 
notching in uterine artery is considered abnormal in obstetric ultrasound evaluation.23 Finally, a significant 
deterioration in functional capacity and/or exercise capacity 1 year postpartum in all patients compared 
with pre-pregnancy values is considered abnormal. 
Statistical and ethical considerations
Sample size calculation. One of the primary aims of the ZAHARA II study is to compare the uteroplacental 
Doppler flow, expressed as pulsatility index in the umbilical artery, during pregnancy between women 
with CHD and healthy controls. A sample size of 160 patients and 60 controls achieves a power of 80% at 
a significance level of 0.05 to detect a difference of 5% higher mean pulsatility index in women with CHD. 
Statistical analysis. Continuous variables with normal distribution will be presented as mean (±SD), 
nonnormally distributed variables as median (with 25th and 75th percentile), and dichotomous variables will 
be presented as absolute numbers and percentages. Comparison of continuous variables between groups 
will be made by independent t-tests or the Mann-Whitney U test, depending on their distribution. For the 
comparison of dichotomous variables, we will use the Χ 2 test or Fisher exact test, where applicable. Uni- 
and multivariable logistic regression analyses will be performed to identify predictors of adverse pregnancy 
outcome. For the analysis of repeated measures within the women with CHD, between the women with 
CHD, as well as between the women with CHD and the healthy controls, we will use multivariate general 
linear models. 
Ethical considerations. The study is conducted according to the principles of the Declaration of Helsinki and 
in accordance with the Medical Research Involving Human Subjects Act (Wet medisch-wetenschappelijk 
onderzoek met mensen). The study design, all research aims, and the specific measurements in the 
ZAHARA II Study have been approved by the medical ethical committee of all participating hospitals. 
New measurements will only be embedded in the study after approval of the medical ethical committee. 
All participants are asked for their written informed consent after having received written and oral 
information about the study. 
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Table 2. Adverse events as defined in ZAHARA II
Primary cardiovascular events during pregnancy, up to 6 m postpartum
Need for urgent invasive cardiovascular procedures
Heart failure: according to the guidelines of the European Society of Cardiology and documented by the attending physician40
Any documented new-onset or symptomatic tachy- or bradyarrhythmia requiring new/extended treatment




Endocarditis: according to the Duke criteria41
Aortic dissection
secondary cardiovascular events during pregnancy, up to 6 m postpartum
NYHA class deterioration: decline of 2 points in NYHA functional class during pregnancy or within 6 m postpartum, compared with prepregnancy 
NYHA class or a persisting deterioration in NYHA functional class postpartum
Primary obstetric events
Assisted delivery: use of forceps, use of a vacuum extractor, or the performance of a cesarean section for delivery on maternal cardiac and medical 
indication, on maternal obstetric indication, or on fetal indication
PIH: systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg or an increase of systolic (>30 mmHg) or diastolic (>15 mmHg) 
blood pressure, in the absence of proteinuria, occurring after ≥20 wk of gestation
PE: PIH with ≥0.3 g/24 h proteinuria
Eclampsia: PE with grand mal seizures
Mild gestational diabetes mellitus: a fasting blood glucose <140 mg/dL (7.8 mmol/L) and 2-h postprandial 140-198 mg/dL (7.8-11 mmol/L)
Severe gestational diabetes mellitus: a random serum glucose value >200 mg/dL (11.1 mmol/L) or a fasting blood glucose value >126 mg/dL (7.0 mmol/L)
HELLP: hemolysis (LDH >250 U/L), elevated liver enzymes (ASAT >40 U/L and ALAT >45 U/L), low platelets (<1.0 × 10.6/mm3) syndrome
Hyperemesis gravidarum: severe, intractable nausea and vomiting, leading to dehydration, loss of weight, metabolic disorders, and hospitalization
Noncardiac death: all cause mortality, except cardiac mortality
Postpartum hemorrhage: blood loss >500 mL (vaginal delivery) or >1000 mL (cesarean section), requiring transfusion or leading to a drop in 
hemoglobin >20 g/L (1.24 mmol/L)
Premature labor: spontaneous onset of labor <37 wk of gestation
Preterm premature rupture of membranes: spontaneous rupture of membrane before the onset of uterine contractions and before 37 wk of 
gestation
Abruptio placentae: premature detachment of the placenta from the wall of the uterus
secondary obstetric events
Amniotomy: mechanical/artificial rupture of membranes
Induction of labor
Prolongation of cervix ripening: omitted dilatation of the portio vaginalis during ≥20 h (nullipara) or ≥14 h (multipara), despite adequate and regular 
uterine contractions
Prolongation of second stage of delivery (primipara >2 h; multipara >1 h)






Table 2 (continued). Adverse events as defined in ZAHARA II
offspring events
Fetal death: intrauterine death >20 wk of gestation
Extended perinatal death: the number of stillbirths from 20 wk of gestation and neonatal death up to 28 d postpartum
Early neonatal death: within 6 d after birth
Late neonatal death: within 7-28 days after birth
Infant death: >28 d and within 1 y after birth
Perinatal death: the total number of stillbirths from 20 wk of gestation and death up to 7 days postpartum
Offspring death: the total number of stillbirths from 20 wk of gestation and death up to 1 y postpartum
Intraventricular hemorrhage: bleeding in the fetal cerebral ventricles
Neonatal respiratory distress syndrome: respiratory insufficiency caused by a developmental insufficiency of surfactant production and structural 
immaturity in the lungs in premature infants
Infections leading to hospital admission
Premature birth: birth <37 wk gestation
Occurrence of CHD
Occurrence of other congenital disease
Small for gestational age: birth weight below the 10th percentile adjusted for gestational age and based on population values
Low birth weight: birth weight <2500 g
Meconium stained amniotic fluid
General events
Anemia: between 18 wk of gestation until 1 wk postpartum: 6.5 mmol/L or 10.5 g/dL42
Hospitalization: all cause hospitalization for more than 1 night
Fever: ≥38.5°C during pregnancy up to 6 m postpartum requiring medical treatment
Infection: infections during pregnancy up to 6 m postpartum requiring medical treatment
AlAT, Alanine aminotransferase; AsAT, aspartate aminotransferase; lDH, lactate dehydrogenase; nyHA, New York Heart Association; 
PIH, pregnancy-induced hypertension; TIA, transient ischemic attack.
Data management and privacy protection. Data are directly entered onto written case record 
forms (CRF) and manually entered into an electronic database by 2 researchers. Random samples 
of all entered data are double checked by other research members to monitor the quality of this 
manual data entry process. Open text fields are copied into the electronic database exactly as they 
are filled in on the CRF. All measurements will be checked by examination of the data including 
their ranges, distributions, means, SD, outliers, and logical errors. Data outliers and missing values 
will be checked on the original CRF. All information in these data sets that enables identification of 
a participant will be excluded. The CRF as well as the data sets include subject unique identification 
numbers that enable feedback about one subject to the data manager but do not enable identification 
of that particular subject. 
Discussion
In the present study, we assess whether changes in cardiovascular, hemodynamic, neurohumoral 
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parameters, and uteroplacental Doppler flow patterns during pregnancy of women with CHD differ 
from age- and parity-matched healthy controls. We also assess the interaction of these changes 
with the occurrence of cardiovascular, obstetric, and offspring events. In addition, we evaluate the 
incidence of permanent changes in cardiovascular parameters 1 year postpartum in women with 
CHD and compare these with matched healthy controls. 
 During normal pregnancy, considerable haemodynamic changes occur.24 Total vascular 
resistance decreases, mainly due to peripheral arterial vasodilatation, mediated by progesterone and 
vasodilators such as nitric oxide as well as a low-resistance flow in the uteroplacental circulation.25,26 
In normal pregnancy, a gradual widening of the maternal spiral arteries occurs early in the first 
trimester due to the invasion of endovascular and interstitial trophoblasts that convert maternal 
spiral arteries closer to the intervillous space. As a consequence, plasma volume, heart rate, and 
CO gradually increase in the first 2 trimesters of pregnancy to maintain adequate organ and 
uteroplacental perfusion while TVR decreases.24,26 Blood pressure drops in the first trimester of 
pregnancy, reaching its lowest point at the end of the second trimester, around 20 weeks of gestation, 
and returns to near prepregnancy levels around term.24,27 Together with the rise in plasma volume, 
the CO rises, which is reflected by an increase in both atrial and ventricular volumes, ventricular 
wall thickness, and the rise of heart rate.24 In normal pregnancy, an increased NT-proBNP level 
can be measured.28 Cardiovascular haemodynamic state returns back to prepregnancy state in most 
women within 6 months postpartum.24,29
 In women with CHD, haemodynamic changes in pregnancy can exceed the compensatory 
possibilities of their compromised circulation, resulting in cardiac complications such as heart 
failure, arrhythmias, and other cardiovascular events. Known predictors of maternal cardiovascular 
events are related to underlying disease as well as to prepregnancy haemodynamic and functional 
status.2,3,9 However, detailed information about changes in ventricular and valvular function as well 
as in CO and TVR and their relationship to the occurrence of cardiovascular events in pregnancy is 
not available. Echocardiographic evaluation before, during, and after pregnancy in our population 
with CHD and in matched healthy pregnant controls will clarify some of the confusion. NT-
proBNP is a well-known marker of heart failure severity.30,31 In women with CHD, NT-proBNP 
has been incompletely evaluated, even outside pregnancy. However, it has been shown that NT-
proBNP correlates positively with New York Heart Association functional class deterioration as 
well as with cyanosis and inversely with ventricular ejection fraction, even in asymptomatic women 
with CHD.32,33 As these parameters predict pregnancy complications in women with CHD, it is 
plausible to hypothesize that NT-proBNP may be an easy and useful method for stratification of 
cardiovascular risk in pregnancy.1-3,9 Moreover, NT-proBNP levels are divergent in hypertensive 
disorders of pregnancy, with a graded increase from normal pregnancy to gestational hypertension 
and PE.34 The frequency of these disorders is increased in women with CHD, and NT-proBNP 







Hypertensive disorders of pregnancy, especially PE, are characterized by impaired trophoblast 
invasion and failure of dilatation of spiral arteries, resulting in high uteroplacental vascular resistance, 
leading to inadequate uteroplacental perfusion and adverse obstetric and offspring outcome, 
including IUGR and PE.6,7 Compromised uterine perfusion with placental dysfunction is reflected 
by abnormal uteroplacental Doppler waveform patterns.5 Abnormal uterine artery pulsatility index 
and notching in early diastolic phase predicts PE, is related to high TVR and low CO, and is 
associated with IUGR and small for gestational age.5 In CHD, a higher incidence of PE and IUGR 
is seen.1-4,35,36 This may be related to a lower CO and higher incidence of heart failure in these women 
that may lead to inadequate uteroplacental perfusion. Therefore, uteroplacental flow patterns may 
differ in women with CHD compared to healthy women and abnormal uteroplacental perfusion 
may be associated with cardiovascular status as well as with offspring outcome. 
 Late effects of pregnancy in CHD Long-term effects of pregnancy in women with CHD 
are incompletely described. In a cohort of women with aortic stenosis, requirement of cardiac 
intervention was the most important late cardiac event after pregnancy.10 In a small group of women 
after Mustard correction, permanent deterioration in functional class, dilatation of right ventricle, 
right ventricular dysfunction, and tricuspid valve regurgitation have been demonstrated.11 In women 
with atrioventricular septal defect, persisting deterioration of atrioventricular valve regurgitation 
was found as well as persisting deterioration of functional class.37 
 Unfortunately, most data are retrospective, and for many defects, no data on mid- and 
late-term outcome after pregnancy are available. In the present study, echocardiographic and clinical 
follow-up will be at least 1 year post pregnancy for all women with CHD. In normal pregnancy, 
exercise capacity declines in the early postpartum period.38,39 Despite the improvement in the 
following 6 months, the pre-pregnancy level is not reached. Whether exercise capacity in women 
with CHD declines more than in healthy pregnant women is uncertain and will be studied in our 
cohort.
Conclusion
The current ZAHARA II study is the first “in vivo” study in women with CHD to evaluate the effect 
of compromised cardiac performance on the uteroplacental circulation and its relationship with 
the occurrence of obstetric events and adverse offspring outcome. By identifying the components 
responsible for pregnancy-related events in women with CHD, we will refine risk stratification that 
will lead to better prepregnancy counseling and may eventually improve treatment of these women.
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Background Adequacy of prepregnancy prediction of cardiovascular and offspring risk associated 
with pregnancy in women with congenital heart disease (CHD) determines for a large part the 
efficacy of counseling prior to and management during pregnancy. The accuracy of the different risk 
assessment tools needs prospective validation and comparison.
Methods In this prospective study, we included 183 women with CHD and determined the outcomes 
of 191 pregnancies. The ZAHARA I and CARPREG cardiovascular risk scores were calculated for 
each pregnancy, as was the total number of cardiovascular (TPc) or offspring risk predictors (TPo) 
from these and other studies combined. Pregnancies were also classified according to the modified 
World Health Organization (WHO) classification of maternal cardiovascular risk and according to 
disease complexity (DC).
Results Maternal cardiovascular events occurred during 19 (9.9%) pregnancies. Offspring events 
occurred during 63 pregnancies (33.0%). Both cardiovascular and offspring event rate increased with 
higher risk scores, higher TPc or TPo, higher WHO class and greater DC. The highest area under 
the curve (AUC) for cardiovascular risk was achieved by the WHO class (AUC: 0.79). CARPREG 
and ZAHARA I offspring risk scores and TPo performed comparably in estimating offspring risk 
(AUC: 0.67, 0.66 and 0.68 respectively). A combination of different risk estimation systems resulted 
in a slightly higher AUC for both maternal and offspring risk. 
Conclusion The WHO classification is the best available individual risk assessment model for 
estimating cardiovascular risk in pregnant women with CHD.  For the estimation of offspring risk, 
the total number of offspring risk predictors, the CARPREG risk model and the ZAHARA I risk 
model are equally predictive.
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Introduction
Pregnancy in women with structural congenital heart disease (CHD) is associated with increased 
maternal cardiac and offspring risk. Maternal cardiac risk consists mainly of arrhythmias and episodes 
of heart failure, whereas the offspring is mainly at risk of premature birth, small for gestational age 
and mortality.1-8 The magnitude of cardiac and offspring risk depends on the underlying CHD 
and is attributable to the complexity of the heart disease and (residual) lesions such as valvular and 
ventricular dysfunction.1,2,7 For the attending cardiologist, adequate risk assessment is essential to 
optimize prepregnancy counseling and pregnancy management.
 Several classifications and risk scores are available to estimate the cardiac and offspring 
risk associated with pregnancy in women with CHD.2,5,7,9,10 Risk assessment models developed by 
the CARPREG investigators and by our own ZAHARA research group provide quantification of 
maternal cardiovascular and offspring risk of pregnancy. Both identified independent predictors of 
maternal cardiovascular and offspring events, as described elsewhere in detail.2,7 Both models attribute 
points to each predictor of maternal cardiovascular risk, thus attributing a certain cardiovascular 
and offspring risk to the pregnancy. Additional predictors were identified by Khairy et al.5 The 
European Society of Cardiology guidelines for the management of heart disease in pregnancy 
advise to estimate maternal risk according to the modified World Health Organization (WHO) 
classification.9,11 This classification integrates knowledge from the total body of literature and takes 
into account the underlying heart disease, ventricular and valvular function, as well as predictors 
identified by several studies. Patients are classified as low, moderate or high risk, or contraindication 
for pregnancy.9,11 Because risk of pregnancy is associated with disease complexity, risk assessment 
may also be performed using a generally accepted disease complexity (DC) classification.1,10,12 A 
prospective external validation and comparison of the abovementioned risk scores and risk assessment 
models has not been performed. 
 We therefore aimed in this prospective multicenter study to provide external validation of 
the CARPREG and ZAHARA I risk scores and to compare the different risk assessment models 
in order to identify the optimal assessment strategy for estimating the risk of cardiovascular and 
offspring events of pregnancy in women with CHD.
Patients and Methods
Design and setting
The ZAHARA II project is an ongoing prospective observational multi-centre cohort study. The 
study design of the ZAHARA II study is published elsewhere; therefore we provide a comprehensive 
summary here.13
Inclusion and exclusion criteria
Pregnant women with structural CHD (≥18 years) followed in any of 8 participating tertiary 






Miscarriage or pregnancy termination prior to 20 weeks gestation was reason for exclusion, as were 
drugs and alcohol abuse. 
Baseline characteristics
Baseline data recorded at the first prenatal visit at the cardiology outpatient clinic (at 20 weeks 
gestation) included: maternal age, obstetric history (including parity), underlying heart disease, prior 
interventions, cardiac sequelae, prior cardiovascular events, co-morbidity, prior and present cardiac 
status including ventricular and valvular function assessed according to the recommendations and 
guidelines of the EAE/ASE, use of medication, alcohol and smoking history.14-17
Risk assessment
Maternal cardiovascular and offspring risk of pregnancy was scored by 2 investigators who were 
ignorant of pregnancy outcome according to the foregoing risk assessment models using the baseline 
characteristics. Based on the presence of independent predictors, the ZAHARA I and CARPREG 
cardiovascular risk scores were calculated.2,7 The ZAHARA I and CARPREG studies published 
predictors of offspring risk, but did not develop a risk score. Since we had full access tot the ZAHARA I 
data, we were able to calculate a ZAHARA I offspring risk score using identical methodology as 
previously described for the maternal risk score.2 (Figure 1) We also developed an offspring risk score 
based on the predictors identified in the CARPREG study by using the exponent value of the odds 
ratio from the independent predictors for offspring events published by the CARPREG investigators 
to weigh the risk factors and attribute points per risk factor.7 No risk percentages per offspring risk 
point were available for this CARPREG offspring risk score. Additionally, the total number of 
(non-overlapping) predictors (TPo; (ZAHARA I, CARPREG and Khairy combined) of cardiovascular 
and offspring events were assessed. Patients were also classified according to the modified WHO 
classification of pregnancy risk and according to disease complexity (DC).9,10
Endpoints
We scored maternal cardiovascular and offspring events for each pregnancy according to the definitions 
used in the CARPREG and ZAHARA I studies. Primary cardiovascular events were: cardiovascular 
mortality, clinically significant (needing treatment) arrhythmia, clinically significant (needing 
treatment) heart failure, thrombo-embolic events (e.g. pulmonary embolism, valve thrombosis or 
deep venous thrombosis), vascular events (e.g. cerebrovascular accidents, myocardial infarction and 
dissection), need for urgent or invasive cardiovascular intervention up to 6 months post partum 
and endocarditis.2,7 Secondary cardiac events were: NYHA class deterioration ≥2 points compared 
to baseline. Offspring events were: premature delivery (delivery <37 weeks gestation), small for 
gestational age birth weight (<10th percentile), respiratory distress syndrome and/or sepsis; intracerebral 
(intraventricular) hemorrhage; recurrence of congenital heart disease and offspring mortality (demise 
in utero [>20 weeks gestation] till the first year postpartum).
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Figure 1. The newly developed ZAHARA I risk score for offspring events during 1302 completed (>20 weeks 
gestation) pregnancies in women with congenital heart disease. Details on the ZAHARA I study can be found 
in reference 2.
Statistical analysis
We used SPSS (version 16.0, SPSS Inc., Chicago, Illinois, USA) and STATA (version 11.0, StatCorp LP, 
College Station, Texas, USA) for statistical analysis. Descriptive statistics for nominal data were 
expressed in absolute numbers and percentages. Mean values and standard deviations were 
presented for normally distributed continuous variables. For non-normal distributed continuous 
variables median and ranges were computed. All P-values are two-sided. External validation of the 
CARPREG cardiovascular risk score and ZAHARA I cardiovascular and offspring risk scores were 
performed by plotting the expected versus observed event rates. We also calculated the area under 
the receiver-operating characteristic (ROC) curve (AUC) to compare the discriminative capacity of 
the different cardiovascular and offspring models. The best combination of risk assessment models 
was assessed by calculating the AUC following logistic models for the different test combinations. 
The P-value for the AUC results from the Χ2 testing for random guess (AUC 0.5). The goodness of 







The study was conducted according to the principles of the Declaration of Helsinki and in accordance 
with the Medical Research Involving Human Subjects Act (WMO). The Medical Ethical Committee 
of all participating hospitals has approved the study. The Dutch Heart Foundation had no role in 
the design, data collection, analysis, interpretation, writing of the manuscript or the decision to 
submit for publication of this manuscript. The corresponding author has full access to all data and 
the responsibility for the submission of this manuscript for publication.
Results
Overall, 201 women with structural CHD were asked to participate and 198 women gave informed 
consent (98.5%). Fifteen women were excluded: 9 women (4.5%) because of late (>12 weeks) 
spontaneous miscarriage and 6 women (3.0%) because of protocol violations (non-compliance (n=4) 
and moving abroad (n=2)). The remaining 183 women had 191 complete pregnancies (≥20 weeks 
of gestation). No women with cyanosis (oxygen saturation <90%), severe pulmonary hypertension 
or Eisenmenger syndrome were included.  The baseline characteristics per pregnancy (n=191) are 
shown in Table 1.  
Maternal cardiovascular events
The distribution of CHD and the primary and secondary cardiovascular events per CHD subtype 
are shown in Table 2. No maternal death occurred. Primary cardiovascular events were observed in 
19 pregnancies (9.9%). Most frequent events were clinically significant arrhythmias (n=11), followed 
by heart failure (n=4) and thrombo-embolic events (n=4). Women with a history of arrhythmia 
(n=14) had 6 cardiovascular events, including 3 arrhythmias. One woman underwent pacemaker 
implantation because of atrioventricular block. Women with a mechanical valve prosthesis (n=11) 
had 6 cardiovascular events. Deterioration of NYHA functional class ≥2 points (secondary 
cardiovascular event) occurred in 38 pregnancies (19.9%).
Offspring events
Offspring events occurred in 66 children, corresponding to 63 pregnancies (33.0%). The distribution 
of offspring events per CHD subtype is shown in Table 2. Twenty-eight children (14.4%) were born 
prematurely (43% due to preterm labor), 29 children (14.9%) were born small for gestational age, 
17 children (8.8%) had respiratory distress syndrome (59% were born premature) and 3 children 
(1.5%) had a cerebral (intraventricular) hemorrhage. Recurrence of CHD occurred in 10 children 
(5.2%). Offspring death occurred in 6 children (3.1%). Four children died in utero (>20 weeks 
gestation). Two children died within 28 days after birth.
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Table 1. Maternal baseline characteristics (prior to pregnancy) at inclusion. N = 191 pregnancies.
N (%)
DeMographics
Maternal age at conception (years ± SD)* 29.3 (±4.4)
Parity status
 0 124 (64.9)
 1 50 (26.2)
 ≥ 2 17 (8.9)
cliNical siTuaTioN
NYHA class I 189 (99.0)
pasT MeDical hisTory
History of arrhythmias 14 (7.3)
Left heart obstruction (PG > 30 mmHg or AVA < 1.5cm2 or MVA < 2 cm2) 14 (7.3)
Left heart obstruction (PG > 50 mmHg or AVA < 1.0 cm2) 2 (1.0)
Systemic ventricular ejection fraction  < 40% 2 (1.0)
Cardiac medication before pregnancy† 27 (14.1)
Systemic AV valve regurgitation# 6 (3.1)
Pulmonary AV valve regurgitation# 9 (4.7)
Mechanical valve prosthesis 11 (5.8)
Cyanotic heart disease** 50 (26.2)
Severe PR and/or depressed subpulmonary ventricular ejection fraction 22 (11.5)
Smoking history 34 (17.8)
Pacemaker / ICD 5 (2.6)
Congestive heart failure 2 (1.0)




Antiplatelet drugs 0 (0.0)
Vitamin K antagonists/Heparin 14 (7.3)
Digoxin 2 (1.0)
Beta-adrenoreceptor blocker 23 (12)
Calcium channel blocker 5 (2.6)
Angiotensin-converting enzyme inhibitor 1 (0.5)
Antiarrhythmic drugs 2 (1.0)
aV, atrioventricular; aVa, aortic valve area; chD, congenital heart disease; icD, intra cardiac defibrillator; lho, left heart 
obstruction; Nyha, New York Heart Association functional class; pg, peak gradient; pr, Pulmonary regurgitation.
* Mean (± Standard Deviation). 
† With the exception of oral anti-coagulation.
# Moderate/ severe.






Table 2. Distribution of cardiovascular and offspring events by primary type of congenital heart 





MATERNAL CONGENITAL LESION N  %                     PCE             SCE
Atrial septal defects 19 9.9 2 (10.5) 5 (26.3) 8** (42.1)
Ventricular septal defects 25 13.1  -   - 2 (8.0) 7 (28.0)
Atrioventricular septal defects 9 4.7 1 (11.1) 1 (11.1) 3 (33.3)
APVR 4 2.1 - - - - 1 (25.0)
Pulmonary stenosis 19 9.9 - - 1 (5.3) 7** (36.8)
AoS/BiAoV 28 14.7 4 (14.3) 11 (39.3) 12 (42.9)
Aortic coarctation 22 11.5 1 (4.5) 3 (13.6) 3 (13.6)
Connective tissue disorders* 9 4.7 1 (11.1)# 2 (22.2) 3 (33.3)
Ebstein’s anomaly 3 1.6 - - -  - 1 (33.3)
Tetralogy of Fallot† 34 17.8 3 (8.8) 6 (17.6) 13 (38.2)
TGA 13 6.8 3 (23.1) 3 (23.1) 3** (23.1)
Fontan circulation 3 1.6 2 (66.7) 2 (66.7) 3 (100.0)
Other corrected complex cyanotic 
heart defects‡
2 1.0 1 (50.0) 2 (100.0) 1 (50.0)
Other§ 1 0.5 1 (100.0) - - 1 (100.0)
Total 191 100 19 (9.9) 38 (19.9) 66†† (34.6)
Values are number of pregnancies. aos/BiaoV, congenital aortic valve stenosis or bicuspid aortic valve; apVr, Anomalous 
pulmonary venous return; pce, primary cardiovascular events; sce, secondary cardiovascular events; Tga, Transposition 
of the great arteries. 
* 1 Loeys Dietz, all others Marfan.
† All corrected; 2 double-outlet right ventricle (Fallot type). 
‡ Pulmonary atresia with combined atrial and ventricular septal defects; truncus arteriosus. 
§ Isolated cleft mitral valve, corrected with mechanical valve (St Jude 25mm).
** 1 twin pregnancy
†† 66 offspring events in 191 pregnancies; including three twin pregnancies. 
Validation of risk scores and comparison of different risk assessment techniques
Figures 2a and 2b show the risk of primary cardiac events during pregnancy per risk assessment 
technique. Overestimation of cardiovascular risk (expected events > observed events) was observed 
in both the ZAHARA I and CARPREG cardiovascular risk scores mainly in the mid- and/or 
high-risk segments, where relatively low number of patients could be included. 
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Figure 2a. Expected and Observed cardiovascular events for the ZAHARA I and CARPREG risk scores.
Figure 2b. Observed cardiovascular event percentages for Total number of Predictors, WHO Classification 






Figure 3a shows the ROC for cardiovascular events for the different risk assessment and estimation 
models. All ROC curves of cardiovascular events deviate significantly from the diagonal line 
(no discrimination), with exception of the CARPREG risk score (AUC 0.62; 95% CI 0.47-0.77; 
P =0.081). The AUC for the ZAHARA I cardiovascular risk score was 0.73 (95% CI 0.59-0.87; P =0.010).
Figure 3a. Receiver Operating Characteristic Curves of cardiovascular events for the different cardiovascular 
risk assessment and estimation models.
*Composite ROC: optimal combination of risk assessment models (WHO class, total no. cardiac predictors 
and DC).The AUC differs significantly between WHO class and 1) CARPREG [P=0.0065] and 2) disease 
complexity [P=0.0093]; as well as between CARPREG and total number of cardiovascular predictors [P=0.035]. 
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Of the 5 cardiovascular risk assessment models, WHO classification had the highest AUC for prediction 
of maternal cardiovascular events (AUC 0.79; 95% CI 0.69-0.89; P <0.0001). A combination of 
WHO classification, TPc and DC had a slightly higher AUC: 0.82; 95% CI 0.72-0.92; P<0.0001). 
Figure 3b. Receiver Operating Characteristic Curves of offspring events for the different offspring risk 
assessment and estimation models.
*Composite ROC: optimal combination of risk assessment models (ZAHARA I offspring risk score and 
CARPREG offspring risk points). The AUC differs significantly between disease complexity and 1) total no. of 
offspring predictors [P=0.0008], 2) ZAHARA I [P=0.0013], and 3) CARPREG [P=0.012]; as well as between 






Figures 4a and 4b show the risk of offspring events in women with CHD per risk assessment 
technique. All risk assessment techniques, with the exception of disease complexity, show an increase 
in offspring risk with increasing risk points, number of predictors or class. Figure 3b shows the ROC 
for offspring events for the different risk assessment and estimation models. All models deviate 
significantly from the reference line, with the exception of disease complexity. A combination of the 
ZAHARA I offspring risk score and CARPREG offspring risk points provided the highest AUC. 
The addition of other risk assessment techniques did not improve the AUC significantly.  
Discussion
This study is the first to validate, compare and integrate the different risk assessment models that 
are used to predict cardiovascular and offspring risk during pregnancy and puerperium in women 
with CHD. All risk assessment models are able to some extent to identify women with CHD at risk 
of primary cardiovascular and offspring events. When comparing the 5 individual risk assessment 
models, the modified WHO classification provides the most adequate individual assessment of 
cardiovascular risk in our cohort. For the assessment of offspring events, the difference in AUC 
is very small between the total number of offspring predictors, the ZAHARA risk score and the 
CARPREG risk points. A combination of the risk factors from ZAHARA I and CARPREG 
provides the highest AUC.
Figure 4a. Expected and Observed offspring events for the ZAHARA I risk score and Observed cardiovascular 
event percentage for CARPREG risk points.
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Maternal cardiovascular events
Our study indicates that pregnancy in women with CHD is relatively safe. The cardiac event rate 
in our cohort is low compared to some other studies.5,18-20 The difference in observed cardiovascular 
events is mainly due to differences in study population and in definition of primary and secondary 
cardiovascular events. Several other studies found comparable cardiovascular event rates.1,2,4,7,21,22 
Our cohort is a relative low risk cohort, with 99% of women in NYHA class I prepregnancy and no 
women with cyanosis or pulmonary arterial hypertension. Well organized prepregnancy counseling 
in the tertiary centers in the Netherlands prevents most high risk women from becoming pregnant, 
which can explain the relatively low event rate in our cohort. 
Validation of cardiovascular risk assessment models
The ZAHARA I risk score discriminates the cardiovascular events in pregnancy better in this cohort 
of women with CHD than the more widely used CARPREG risk score. The AUC for ZAHARA 
I is higher and it deviates significantly from random guess (AUC=0.5), unlike the CARPREG risk 
score. The low prevalence of systemic ventricular dysfunction and high NYHA class as well as the 
absence of mitral valve stenosis in our cohort is the most likely explanation.
Figure 4b. Observed offspring events percentages for Total number of offspring predictors, WHO Classification 






The CARPREG risk score overestimates maternal cardiovascular risk in our cohort, in line with 
other studies.4,5,21,22
 Overall, in our cohort of women with CHD, the WHO classification discriminates best for 
cardiovascular events. This is not surprising since the WHO classification integrates all knowledge 
about maternal risk, including known contraindications for pregnancy which are ignored in the 
CARPREG and ZAHARA I risk scores, as well as known predictors found by CARPREG and other 
studies, underlying heart disease and other morphological and clinical variables. A disadvantage of 
the WHO class may be that expert knowledge is sometimes required, especially when choosing 
between WHO class II and class III. Whether physicians with less expertise might make a different 
choice than a more experienced physician was not assessed in our study. Finally, it is important that 
WHO class I has a negative predictive value of 100% for maternal cardiovascular events, indicating 
that pregnancy is relatively safe in these women.
 A combination of the risk classification systems from the WHO class with total number 
of cardiovascular predictors and disease complexity provides the most adequate assessment 
of cardiovascular risk in pregnancy. This illustrates that integration of clinical information and 
predictors or population-based information has additional value on top of individual risk assessment 
models.
Offspring events
The offspring event rate observed in our cohort is comparable to most other studies in women with 
CHD.1,2,4-7,18-20,23,24 Offspring death occurred in 3.1% of pregnancies. Although offspring mortality 
in our cohort is in accordance with previous studies in women with CHD, it is much higher than in 
general Dutch population.2,4-7,20,25 Also premature births, small for gestational age and recurrence of 
CHD occurred more often than would be expected in the general Dutch population.
Validation of offspring risk assessment models
The estimation of offspring risk by the ZAHARA I offspring risk score proved to be fairly accurate. 
The CARPREG risk score also identified pregnancies with a higher risk of offspring events, however 
since no risk percentage could be attributed to the CARPREG risk points a comparison with the 
ZAHARA I risk model could not be made.
 The risk models predicting offspring events appear to be interchangeable, because the 
differences in AUC are very small, especially between ZAHARA I, CARPREG and TPo. 
This is explained by the huge overlap between the risk factors found by ZAHARA I and CARPREG. 
The WHO class was not designed to assess offspring events in women with CHD. Therefore it does 
not take into account factors such as maternal age, parity, smoking and twin pregnancy, which are 
known risk factors for offspring events. This is probably also the main reason why disease complexity 
alone is not an accurate predictor of offspring events. 
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Limitations and strengths
The participation rate was excellent with 98% of women providing written informed consent 
and only 2 women lost to follow up. Although inclusion rate is high, some limitations need to 
be addressed. Some inclusion bias might have been introduced, since only pregnancies of ≥20 
weeks were taken into account. Additionally no patients with a high risk of maternal death, such 
as Eisenmenger syndrome, could be included. Nevertheless, the distribution of the CHD subtypes 
adequately represents a tertiary hospital pregnant CHD cohort. Additionally, the available risk 
prediction systems that we validated did not allow prediction of more threatening events such as 
heart failure separately from more innocent events such as supraventricular arrhythmias. Despite the 
limitations, our study is the first prospective study to validate, compare and integrate the available 
risk estimation models to predict the cardiovascular risks during pregnancy in women with CHD.
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Background Pregnant women with congenital heart disease (CHD) are susceptible to cardiovascular, 
obstetric and offspring complications.  In women with CHD cardiac dysfunction may compromise 
uteroplacental flow and contribute to the increased incidence of obstetric and offspring events.
Methods We compared clinical, laboratory, echocardiographic and uteroplacental Doppler flow 
(UDF) parameters at 20 and 32 weeks of gestation, and pregnancy outcome in women with CHD 
and healthy women. We related cardiovascular parameters to UDF parameters and pregnancy 
outcome in women with CHD.
Results We included 209 women with CHD and 70 healthy women. Cardiovascular parameters 
(N-terminal pro-B-type natriuretic peptide (NT-proBNP), left and right ventricular function) 
differed between both groups. UDF parameters were impaired in CHD women (umbilical artery 
pulsatility and resistance index at 32 weeks in CHD versus healthy women P=0.0085 and P=0.017). 
Women with CHD had more obstetric and offspring events than healthy women (58.9% versus 
32.9%, P<0.0001; and 35.4% versus 18.6%, P=0.008). Impaired UDF was associated with adverse 
obstetric and offspring outcome. At multivariate analysis, cardiovascular parameters prepregnancy 
and at 20 weeks were associated with UDF (umbilical artery resistance index at 32 weeks): right 
ventricular function (tricuspid annular plane systolic excursion) (P=0.002), high NT-proBNP 
(P=0.085), and systemic (P=0.001) and pulmonary (P=0.045) atrioventricular valve regurgitation.
Conclusion UDF parameters differ between healthy and CHD women. UDF parameters are 
associated with cardiovascular function and obstetric and offspring outcome in women with CHD. 
Compromised UDF may be a mechanism involved in the high incidence of adverse offspring and 
obstetric outcome in women with CHD.
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Introduction
The extensive evolution of cardiac surgery for congenital heart disease (CHD) has resulted in a 
large population of adult women with CHD. Many of them pursue pregnancy. Pregnancy in these 
women is associated with cardiovascular complications. Moreover, also obstetric and offspring 
complications are more prevalent than in healthy pregnant women.1-5 In women with CHD offspring 
complications are related to maternal cardiac function.5 However, the underlying pathophysiology 
of this relationship is incompletely unraveled. In healthy women with intrauterine growth restriction 
or hypertensive disorders of pregnancy, the process of placentation is disturbed resulting in abnormal 
uterine and umbilical artery Doppler flow patterns.6 Co-existing cardiac function abnormalities 
have been demonstrated.7,8 However, in women with CHD, the relation between cardiac function 
(as expressed in N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels and echocardiographic 
parameters), uteroplacental Doppler flow (UDF) patterns and offspring complications has not been 
investigated. We hypothesized that cardiac dysfunction in women with CHD results not only in 
cardiovascular complications, but also leads to disturbed placentation with abnormal UDF patterns, 
thus compromising normal growth and development of the fetus and contributing to complications 
in pregnancy. The objective of the present study is therefore to compare cardiovascular clinical, 
biochemical and echocardiographic parameters as well as UDF patterns of pregnant women with 
CHD with healthy pregnant women. Moreover, we relate maternal cardiovascular parameters in 
women with CHD to UDF patterns, and relate these to obstetric and offspring outcome.
Patients and Methods
Design and setting
This prospective observational multi-centre cohort study was conducted between March 2008 and 
August 2011. The study design was published previously and is summarized below.9
Patient selection
Female patients with structural CHD (age ≥ 18 years) reporting pregnancy with a duration ≤20 
weeks and followed in one of the 8 participating tertiary hospitals who provided written informed 
consent participated in the study. Miscarriages or termination before 20 weeks gestation and twin 
pregnancies were excluded, as were women with known illicit drug or alcohol abuse. The study was 
approved by the Medical Ethics Committee of all participating hospitals. 
Preconception characteristics
Baseline data recorded at the first prenatal visit (20 weeks gestation) included: maternal age, obstetric 
history, cardiovascular history, co-morbidity, prepregnancy cardiac status and echocardiographic 
recordings (including systemic and pulmonary ventricular function as well as valvular function), use 






Evaluation at 20 and 32 weeks
Participants underwent at 20 and 32 weeks of gestation clinical and laboratory evaluation (including 
serum haemoglobin and NT-proBNP), echocardiographic examination, as well as uteroplacental 
Doppler flow registration (pulsatility index (PI) and resistance index (RI) of umbilical artery and of 
right and left uterine artery, and presence of early diastolic notching (EDN)). All echocardiographic 
recordings were made on commercially available Philips or Vingmed General Electrics ultrasound 
equipment. Echocardiograms were evaluated off-line by 3 experienced investigators and chamber 
quantification, ventricular and valvular function were assessed according to guidelines.10-13 
Obstetric and offspring events
Extensive definitions of obstetric and offspring events were published previously and are summarized 
below.9
Obstetric events: non-cardiac death, pregnancy induced hypertension, pre-eclampsia, eclampsia, 
gestational diabetes, hemolysis, elevated liver enzymes, low platelet (HELLP) syndrome, hyperemesis 
gravidarum, assisted delivery, postpartum hemorrhage, premature labor, preterm premature rupture 
of membranes (PPROM) and abruptio placentae. 
Offspring events: fetal death, neonatal death, intraventricular hemorrhage, neonatal respiratory 
distress syndrome, infections leading to hospital admission, neonatal intensive care unit admission, 
premature birth, occurrence of CHD, occurrence of other congenital disease, small for gestational 
age and low birth weight.
Statistical analysis
We used SPSS (IBM SPSS Statistics, version 19.0, SPSS Inc., Chicago, Illinois, USA) and STATA 
(version 12.0, StatCorp LP, College Station, Texas, USA) for statistical analysis. Continuous variables 
with normal distribution are presented as mean with standard deviation (±SD), non-normally 
distributed variables as median with interquartile ranges (IQR)), and dichotomous variables are 
presented as absolute numbers with percentages. Cardiovascular parameters and UDF parameters 
at 20 and 32 weeks gestation as well as pregnancy outcome were compared between women with 
CHD and healthy women. Comparison of continuous variables between groups was performed with 
Student’s t test or Mann-Whitney U test, depending on distribution, with and without logarithmic 
transformation. For the comparison of dichotomous variables, we used the Χ 2 test or Fisher exact 
test, as appropriate. A P value <0.05 was considered statistically significant and all P values are 
two-sided. Uni- and multivariable linear and logistic regression analyses were performed to assess 
associations between cardiovascular parameters and UDF parameters as well as between UDF 
parameters and obstetric and offspring outcome. In addition, variables at 20 weeks gestation were 
adjusted for prepregnancy variables that were significantly associated with the studied endpoints 
(P<0.05) and variables at 32 weeks gestation were adjusted for variables that were significantly 
associated with the studied endpoints prepregnancy and at 20 weeks gestation. Variables that were 
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strongly associated with the studied endpoints (P<0.10) entered the multivariable model. The final 
multivariate model was constructed by backward deletion of the least significant characteristic, with 
a criterion for deletion of P≥0.10.
Results
Prepregnancy characteristics 
We recruited 234 pregnant women with CHD.  Twenty-five women were excluded, because of 
miscarriage (n=11), serious protocol violation (n=6), twin pregnancy (n=4) or withdrawal of informed 
consent (n=4). Simultaneously 70 healthy, age and parity matched pregnant control women with a 
singleton pregnancy were recruited. 
CHD and healthy cohorts were well balanced with respect to maternal age at conception (28.7±4.4 
versus 29.2±4.5, P=0.44), parity (64.1% versus 62.9% nulliparous, P=0.46), ethnic origin (95.7% 
versus 97.1% Caucasian, P=0.35) and prepregnancy body mass index (BMI) (23.5±3.9 versus 
23.1±3.9, P=0.56). More healthy women smoked prepregnancy compared to CHD women (20.7% 
versus 33.3%, P=0.03). Table 1 shows prepregnancy data of the CHD cohort. Cardiac medication 
was used prepregnancy by 15.8% of women with CHD, 7.2% were on anticoagulation therapy and 
12.4% used a beta-blocker. Sinus rhythm prepregnancy was present in 88% (N=185). Systemic 
ventricular ejection fraction was known in 161 CHD women and was below 45% in 8.1% of these 
women. Prepregnancy right ventricular (RV) function (tricuspid annular plane systolic excursion 
(TAPSE)) was known in 138 CHD women; RV dysfunction (TAPSE <16 mm) existed in 14.5% of 
these women.
Cardiovascular and UDF parameters in pregnant women with CHD and healthy 
pregnant women
NYHA functional class deterioration ≥2 class at 32 weeks compared to prepregnancy occurred more 
often in CHD than in healthy women: 10.1% versus 0%, P=0.003. 
We compared laboratory, echocardiographic and UDF parameters between CHD and healthy 
cohorts at 20 and 32 weeks gestation (Table 2). NT-proBNP was higher throughout pregnancy 
in women with CHD and decreased in both cohorts, the decrease was significantly more in CHD 
women (P=0.04). Systemic ventricular mass/body surface area (BSA) was higher and increased 






Table 1.  Maternal prepregnancy characteristics in women with CHD (N=209)
N (%)
CHD Disease CoMplexiTy  
 Simple 59 28.2
 Moderately complex 140 67.0
 Complex 10 4.8
lesioNs
Left sided lesions 57 27.3
 Aortic stenosis / bicuspid aortic valve 29 50.9
 Aortic coarctation 26 45.6
 Other 2 3.5
Right sided lesions 64 30.6
 Ebstein’s anomaly 4 6.3
 Pulmonary stenosis 21 32.8
 Tetralogy of Fallot 39 60.9
Shunt lesions 60 28.7
 Abnormal pulmonary venous return 6 10
 Atrial septal defect 20 33.3
 Atrioventricular septal defect 8 13.3
 Ventricular septal defect 26 43.3
Connective tissue disease 9 4.3
 Marfan syndrome 8 88.9
 Loeys-Dietz syndrome 1 11.1
Complex CHD 19 9.1
 Transposition of great arteries (Mustard/Senning operation) 11 57.9
 Transposition of great arteries (arterial switch operation) 2 10.5
 Congenitally corrected transposition of great arteries 1 5.3
 Fontan circulation 3 15.8
 Other complex CHD 2 10.5
MeDiCal HisTory
History of heart failure 5 2.4
History of arrhythmia 19 9.1
History of hypertension 14 6.7
History of diabetes 2 1.0
Pacemaker  7 3.3
Mechanical valve prosthesis 11 5.3
Biological-valve prosthesis  20 9.6
New york HearT assoCiaTioN (NyHa) fuNCTioNal Class
NYHA functional class I 159 76.1
NYHA functional class II 49 23.4
NYHA functional class III 1 0.5





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Systemic ventricular ejection fraction did not change significantly in both groups. Several diastolic 
systemic ventricular function parameters were significantly worse in CHD women: systemic 
ventricular annular velocity (E’) was lower and diastolic filling pressure (E/E’) higher; change 
during pregnancy was comparable between groups. RV systolic function (represented by TAPSE 
and systolic annular velocity) was worse in CHD and decreased significantly in CHD women only 
(P=0.017 and P=0.009, respectively).5
 Figure 1 shows UDF parameters at 20 and 32 weeks. Uterine and umbilical artery PI and RI 
were higher throughout pregnancy in the CHD group and decreased in both groups.
Figure 1. Uteroplacental Doppler flow parameters: pulsatility index and resistance index of mean of right and 
left uterine artery and of umbilical artery at 20 and 32 weeks of pregnancy, in women with CHD and healthy 
women.
Pregnancy outcome in CHD and healthy women
Cardiovascular events occurred in 10.5% in the CHD and 0% in the healthy group. UDF parameters 
were not significantly associated with cardiovascular events.
 Obstetric events occurred in 58.9% of CHD and 32.9% of healthy women (P<0.005). CHD 
women had more planned caesarean sections (13.4% versus 1.4%, P=0.003) and assisted deliveries 
(47.4% vs 25.7%, P=0.001). Several obstetric events occurred more often in CHD women without 
the differences reaching statistical significance: hypertensive disorders of pregnancy (17.7% versus 
11.4%), pre-eclampsia (5.7% versus 1.4%) and PPROM (6.7 versus 2.9%). In women with CHD, 
high umbilical artery RI (>90th percentile of healthy group) at 32 weeks was associated with obstetric 
events (P=0.049).
 CHD women had shorter gestational age at delivery than healthy women (38.3 versus 39.7 
weeks, P<0.005) and their babies had lower birth weight (3036 versus 3578 gram, P<0.005). Offspring 
events occurred more often in CHD than in healthy women: 35.4% versus 18.6%, (P=0.008). 
More children of women with CHD were small for gestational age (16.3% versus 4.3%, P=0.008). 
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Congenital heart disease occurred in 4.8% of offspring of CHD women versus 0% of healthy 
women’s offspring (P=0.176). Offspring death occurred in 2.9% of the CHD group and 0% of 
the healthy group, premature birth occurred in 12.4% versus 5.7% (P=0.18). UDF patterns of 
women with CHD were associated with offspring events (Figure 2). Multivariate predictors of 
offspring events, corrected for age and parity, were: preconception use of anticoagulation therapy 
(OR 6.29, 95% CI 1.55-25.4, P=0.010) and severe pulmonary regurgitation (OR 2.88, 95% CI 
1.08-7.72, P=0.035); at 20 weeks gestation: uterine artery PI (OR 3.28, 95% CI 1.19-9.02, 
P=0.021 and mean arterial pressure (OR 1.06, 95% CI 1.01-1.11, P=0.021); at 32 weeks gestation: 
NT-proBNP > twice the upper limit of normal (>256 ng/l) (OR 10.3, 95% CI 2.00-53.5, P=0.005) 
and aortic stenosis (peak velocity >3m/s)(OR 5.91, 95% CI 1.01-34.5, P=0.049. In a final multivariate 
model including all of the abovementioned parameters simultaneously, all effects remained 
significant.
Relation of cardiovascular parameters and UDF indices
We related maternal cardiovascular parameters to UDF parameters. PI and RI were not measured 
both in all patients. Univariate analysis revealed the following variables to be associated with uterine 
artery RI (20 weeks): parity, preconception heart rate, systemic atrioventricular valve regurgitation 
and left atrial volume; and at 20 weeks heart rate, use of cardiac medication and TAPSE. Multivariate 
analysis rendered parity (β=0.04, P=0.048), resting heart rate at 20 weeks (β=-0.002, P=0.006) 
and use of cardiac medication at 20 weeks (β=0.08, P=0.035) significant. Multivariate models for 






Figure 2. Relation of uteroplacental Doppler flow parameters and offspring outcome. A: Uterine and umbilical 
artery PI and offspring events. B: Uterine and umbilical artery RI and offspring events. C: Uterine artery early 
diastolic notch and offspring events. Uta, Uterine artery; Uma, umbilical artery; EDN, early diastolic notch; 




Table 3. univariate and multivariate regression analysis for the prediction of umbilical artery ri at 
32 weeks of gestation
β 95% Ci P
association of 20 wk variables with umbilical artery ri 32 wk
Age 0.004  0.001 – 0.008 0.006
Smoking during pregnancy 0.045  -0.000 – 0.090 0.051
High NT-proBNP* 0.024  -0.003 – 0.050 0.085
Systemic AV valve regurgitation 0.068  0.027 – 0.109 0.001
association of 20 wk variables with umbilical artery ri 32 wk after adjusting for preconception variables
Age 0.003  0.000 – 0.007 0.040
Systemic AV valve regurgitation 20 weeks 0.056  -0.011 – 0.101 0.016
Pulmonary AV valve regurgitation preconception 0.035  0.001 – 0.067 0.045
TAPSE preconception      -0.004  -0.007 –  -0.002 0.002
ri, resistance index; NT-probNp, N-terminal pro B-type natriuretic peptide; av, atrioventricular; Tapse, tricuspid annular 
plane systolic excursion.
*High NT-proBNP: >95th percentile of healthy controls (>128 ng/l)
Discussion
Our study is the first to compare UDF parameters of CHD and healthy women and relate these 
to cardiovascular parameters and to events and outcome in pregnant women with CHD. Our data 
show that UDF and cardiovascular parameters differ between women with CHD and healthy 
women. In women with CHD, ventricular function as well as valvular function are related to UDF, 
while UDF is predictive of obstetric and offspring events. 
 Adequate uteroplacental blood flow is necessary for normal pregnancy outcome. 
Vascular remodeling of the uteroplacental circulation guarantees sufficient flow throughout pregnancy. 
This remodeling is characterized by vascular widening of the uterine circulation, which is mediated 
by endovascular trophoblast invasion of uterine arteries, increased shear stress, and angiogenic and 
humoral factors.14 The remodeling process results in a low resistance in the uteroplacental circulation. 
Abnormalities in the placentation process can result in elevated resistance and pulsatility indices, 
which are associated with adverse maternal and offspring outcome, particularly pre-eclampsia and 
intrauterine growth retardation.5,15 In our study women with CHD had significantly more obstetric 
and offspring complications than healthy women. This included a four-fold increase in the incidence 
of pre-eclampsia and of children born small for gestational age. The increased incidence of these 
complications is in line with previous studies1, 3-5,16-18 The association of abnormal UDF patterns 
and obstetric and offspring outcome, which is well established in the general population, was also 
present in our women with CHD. More important, UDF indices indicated a higher resistance in the 
uteroplacental circulation throughout pregnancy in women with CHD compared to healthy women. 






both before and during pregnancy. Cardiac parameters associated with UDF in the multivariate 
model included preconception right ventricular function and NT-proBNP. NT-proBNP and BNP 
are well-established biomarkers of heart failure and BNP is a predictor of maternal cardiovascular 
pregnancy complications.19 NT-proBNP or BNP have not previously been investigated in relation to 
offspring outcome in women with heart disease. We found elevated NT-proBNP to be associated with 
both abnormal UDF and offspring complications. Prepregnancy NT-proBNP was unfortunately 
not available. NT-proBNP may become a useful tool in pregnancy risk estimation in women with 
heart disease. Cardiac medication was related to uterine artery RI. The use of cardiac medication 
is also a predictor of maternal cardiac complications and is probably related to disease severity.5 
Interestingly, both systemic and pulmonary atrioventricular valve regurgitation were associated with 
UDF parameters. Atrioventricular valve regurgitation is regarded as relatively harmless for the mother 
and her child, because the decrease in vascular resistance that accompanies pregnancy may reduce 
regurgitation. However, recent research indicates that mitral regurgitation does predict maternal 
cardiovascular complications and induces unfavorable cardiac remodelling.5,20 A recent study 
demonstrated that mitral prolapse is associated with preterm delivery.21 Therefore, atrioventricular 
valve regurgitation cannot be regarded as completely innocent. Our results indicate that placental 
flow may be compromised by atrioventricular valve regurgitation, possibly by reducing cardiac 
output. Valve stenosis did not predict UDF, which might be explained by a lower prevalence than 
regurgitant lesions. In addition to cardiac parameters, also parity, age and smoking were associated 
with UDF. 
 Our results confirm the hypothesis that prepregnancy cardiac dysfunction is involved in the 
pathogenesis of abnormal placentation. The importance of this finding reaches beyond explanation 
of the high obstetric and offspring complication rate in women with CHD.
 Evidence from the literature indicates a relationship in the general population between 
previous pre-eclampsia or intra-uterine growth restriction and the later occurrence of acquired 
cardiovascular disease in the mother.22,23 A recent study revealed an association of uterine RI during 
pregnancy with prepregnancy uterine blood flow.24 Based on these data it has been hypothesized 
that pregnancy complications, particularly pre-eclampsia and intra-uterine growth restriction, 
reveal latent cardiovascular abnormalities that may be already present before pregnancy. Our study 
adds strong evidence to support this hypothesis, since in our women with CHD cardiac function 
prepregnancy related to abnormal UDF and adverse offspring outcome.
Strengths and limitations
Our study is the first to investigate UDF in pregnant women with cardiac disease. Several 
limitations must be considered. We designed our study to include pregnant women with various 
underlying congenital cardiac diseases. The heterogeneity of our population may have caused 
underrepresentation not only of individual diseases but also of specific cardiac dysfunctions. 
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This may have impacted the robustness of our prediction models. Moreover, since the study included 
women when they were already pregnant, collection of prepregnancy data was retrospective, and 
missing data were inevitable. Additionally, in this multicentre study, sometimes deviation from the 
protocol occurred, while complex disease often prevented accurate measurements of chamber size 
and function; therefore not all data were available in all patients. Our composite outcome variable 
combined all offspring events. However, some offspring events may not be influenced by UDF 
(i.e. recurrence of congenital heart disease). Despite these limitations, we were able to demonstrate 
that cardiac function in women with CHD is associated with UDF and pregnancy outcome. 
Our study results lead to an improved understanding of the pathophysiology of offspring events in 
women with CHD, and may also contribute to a better insight in the pathophysiology of offspring 
complications in the general population.
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In the last decades the number of women with congenital heart disease (CHD) reaching childbearing 
age is steadily increasing. Most of these women have a pregnancy wish and although many women 
with CHD tolerate pregnancy well, complication rate is still considerable. Due to the great diversity 
of the CHD population, outcome of pregnancy in women with CHD is not easy to predict. In this 
thesis we focus on the identification of predictors of adverse pregnancy outcome in women with 
CHD. Our data are meant to give guidance to recognize women at increased risk timely so adverse 
outcome can be prevented or at least limited to a minimum.
In the FIRST PART we addressed in retrospect complications and predictors of adverse pregnancy 
events in women with CHD.
Chapter 1 gave an overview of the prevalence and clinical significance of pregnancy related adverse 
outcome in women with CHD. We described the normal physiology of pregnancy and the 
pathophysiological consequences of haemodynamic changes of pregnancy for women with CHD. 
In addition, we reviewed the known predictors of adverse outcome that can be used for risk 
stratification in women with CHD. In chapter 2 we focused on pregnancy and outcome in women 
with tetralogy of Fallot. We identified women with tetralogy of Fallot using 2 congenital heart 
disease registries. Within this cohort, 123 pregnancies occurred, that lasted longer than 20 weeks. 
Cardiovascular events occurred in 8% of pregnancies, while obstetric and offspring events occurred 
in 59% and 34% of pregnancies. Offspring death occurred in 6% of pregnancies. We identified 
several predictors of adverse cardiac and offspring outcome in pregnancies of women with tetralogy 
of Fallot. The most important independent predictor for both cardiovascular and offspring events 
was the use of cardiac medication before pregnancy. Palliative surgery before correction was also 
an independent predictor of adverse offspring outcome. In addition, we found that the occurrence 
of maternal cardiovascular events during pregnancy was highly associated with offspring events. 
In chapter 3 we gave an overview of complications during pregnancy and predictors of adverse 
pregnancy events in the largest group of women with CHD ever assessed (n=1302). The most 
prevalent cardiac complications during pregnancy in women with CHD were arrhythmias (5%) 
and heart failure (2%). Factors independently associated with maternal cardiovascular events were 
the presence of cyanotic heart disease (corrected or uncorrected), the use of cardiac medication 
before pregnancy, left heart obstruction, presence of a mechanical valve and systemic or pulmonary 
atrioventricular valve regurgitation. The most prevalent obstetric complications were hypertensive 
disorders of pregnancy (12%). The most prevalent neonatal complications were premature birth 
(12%), small for gestational age (14%), and mortality (4%). Cyanotic heart disease, presence of a 
mechanical valve, maternal smoking, multiple gestations and the use of cardiac medication were 
independent predictors of adverse offspring outcome. In addition, the most widely used model for 






We found that the CARPREG risk score overestimated the risk of cardiovascular events in women 
with CHD and proposed a new CHD-specific prediction model for the prediction of adverse 
cardiovascular events in women with CHD.
The SECOND PART of this thesis covered the prospective assessment of predictors of adverse 
events in pregnancy in women with CHD.
Chapter 4 described the design and rationale of the prospective ZAHARA II study that was designed 
to assess whether changes in cardiovascular, haemodynamic, neurohumoral parameters, and 
uteroplacental Doppler flow patterns during pregnancy in women with CHD differed from age- and 
parity-matched healthy controls. Another aim of the ZAHARA II study was to assess the interaction 
of these changes with the occurrence of cardiovascular, obstetric, and offspring events. Finally the 
ZAHARA II study was designed to compare and validate the existing risk estimation models in a 
prospective cohort of women with CHD. In Chapter 5 the various available risk estimation models 
were validated and mutually compared using the ZAHARA II population. In this prospective study, 
we determined the outcomes of 191 pregnancies. The ZAHARA I and CARPREG cardiovascular 
risk scores were calculated for each pregnancy, as was the total number of cardiovascular or offspring 
risk predictors from these and other studies combined. Pregnancies were also classified according to 
the modified World Health Organization (WHO) classification of maternal cardiovascular risk and 
according to disease complexity. Maternal cardiovascular events occurred in 10% of pregnancies. 
Offspring events occurred in 33% of pregnancies. Both cardiovascular and offspring event rate 
increased with higher ZAHARA I or CARPREG risk scores, higher total number of cardiovascular 
or offspring risk predictors, higher WHO class and greater disease complexity. When comparing the 
5 individual risk assessment models, the modified WHO classification provided the most adequate 
individual assessment of cardiovascular risk in the ZAHARA II cohort. For the assessment of 
offspring events, the difference in area under the curve was very small between the total number 
of offspring predictors, the ZAHARA risk score and the CARPREG risk points. A combination 
of the risk factors from ZAHARA I and CARPREG provided the highest area under the curve for 
the assessment of offspring events. In Chapter 6 the main outcome of the ZAHARA II study was 
described. To prove that in women with CHD cardiac dysfunction compromises uteroplacental 
flow and contributes to the increased incidence of events, we compared cardiovascular clinical, 
biochemical and echocardiographic parameters as well as uteroplacental doppler flow patterns of 
pregnant women with CHD with healthy pregnant women and related these parameters to maternal 
and offspring outcome in women with CHD. We included 209 women with CHD and 70 healthy 
women. Cardiovascular parameters (NT-proBNP, left and right ventricular function) differed 
between both groups. Uteroplacental Doppler flow parameters were impaired in women with CHD 
compared to in healthy women. Women with CHD had more obstetric and offspring complications 
than healthy women (58.9% versus 32.9%, P<0.0001; and 35.4% versus 32.9%, P=0.008). 
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An impaired uteroplacental Doppler flow was associated with adverse obstetric and offspring 
outcome in women with CHD. Abnormal cardiovascular parameters prepregnancy and at 20 weeks 
were associated with impaired uteroplacental Doppler flow: high NT-proBNP, decreased tricuspid 
annular plane systolic excursion, mitral and tricuspid regurgitation predicted a higher umbilical 
artery resistance index at 32 weeks. Therefore a compromised uteroplacental Doppler flow may be a 
mechanism involved in the high incidence of offspring and obstetric events in women with CHD.
Future perspective
Until now, most research concerning pregnancy in women with congenital heart disease focused on 
the incidence of pregnancy complications. Some studies identified predictors of adverse outcome. 
In the present thesis we added some new predictors as well as new prediction models to provide 
aid in the assessment of women at increased risk. We also compared several risk assessment models 
and methods to further improve risk assessment and thereby outcome of pregnancy in women with 
CHD. To improve risk assessment in the future it is important to further specify predictors and 
develop risk models for specific subgroups of women with different CHD. For this purpose larger 
multicentre cohort studies are essential; therefore researchers should join forces.
Cardiac parameters are not only associated with cardiac outcome in pregnancy. We also demonstrated 
in the ZAHARA II study that cardiac dysfunction in women with CHD affects uteroplacental flow. 
In the general pregnant population, inadequate uteroplacental circulation is strongly associated with 
adverse obstetric and offspring outcome, and this was also confirmed in our CHD population. 
Further studying the relation of cardiac function as well as of vascular/endothelial function and 
uteroplacental Doppler flow in women with CHD may further elucidate the mechanism of adverse 



















In de laatste decennia is het aantal vrouwen met een aangeboren hartafwijking die de vruchtbare 
leeftijd bereikt gestaag toegenomen. De meeste van deze vrouwen hebben een zwangerschapswens 
en hoewel een zwangerschap door de meeste vrouwen met een aangeboren hartafwijking goed wordt 
verdragen, is het aantal complicaties toch aanzienlijk. Door de grote diversiteit in de populatie van 
patiënten met een aangeboren hartafwijking zijn zwangerschapscomplicaties bij vrouwen met een 
aangeboren hartafwijking niet eenvoudig te voorspellen. In dit proefschrift richten we ons op de 
identificatie van voorspellers van zwangerschapscomplicaties bij vrouwen met een aangeboren 
hartafwijking. Het doel van onze bevindingen is om een handvat te geven in het tijdig herkennen 
van vrouwen met een verhoogd risico, zodat zwangerschapscomplicaties kunnen worden voorkomen 
of tenminste tot een minimum kunnen worden beperkt.
In het EERSTE DEEL van dit proefschrift hebben we ons in retrospect gericht op complicaties en 
voorspellers van zwangerschapscomplicaties bij vrouwen met een aangeboren hartafwijking. 
Hoofdstuk 1 geeft een overzicht van de prevalentie en de klinische relevantie van zwangerschap 
gerelateerde complicaties bij vrouwen met een aangeboren hartafwijking. We hebben de normale 
fysiologie van de zwangerschap en de pathofysiologische gevolgen van de hemodynamische 
veranderingen van een zwangerschap voor vrouwen met een aangeboren hartafwijking beschreven. 
Bovendien, hebben we de bekende voorspellers van zwangerschapscomplicaties besproken die 
gebruikt kunnen worden voor risicostratificatie van vrouwen met een aangeboren hartafwijking. 
Hoofdstuk 2 richt zich op zwangerschap en uitkomst bij vrouwen met de tetralogie van Fallot. 
We hebben vrouwen met de tetralogie van Fallot geïdentificeerd in 2 registraties voor personen 
met een aangeboren hart afwijking. Binnen dit cohort vonden 123 zwangerschappen plaats 
die langer stand hielden dan 20 weken. Cardiovasculaire complicaties traden op bij 8% van de 
zwangerschappen, terwijl obstetrische complicaties en complicaties bij het kind bij respectievelijk 
59% en 34% van de zwangerschappen plaatsvonden. In 6% van de zwangerschappen overleed 
het kind. We hebben diverse voorspellers van cardiale complicaties en complicaties bij het kind 
geïdentificeerd voor zwangerschappen van vrouwen met de tetralogie van Fallot. De belangrijkste 
onafhankelijke voorspeller voor zowel cardiovasculaire complicaties als complicaties bij het kind 
was het gebruik van cardiale medicatie vóór de zwangerschap. Een palliatieve operatie voorafgaand 
aan een correctie bij de moeder was ook een onafhankelijke voorspeller van complicaties bij het 
kind. Tenslotte  hebben we gevonden dat het vóórkomen van cardiovasculaire complicaties bij de 
moeder tijdens de zwangerschap sterk gerelateerd was aan het vóórkomen van complicaties bij het 
kind. In hoofdstuk 3 hebben we een overzicht gegeven van complicaties rond de zwangerschap en 
voorspellers van deze complicaties in de grootste groep vrouwen met een aangeboren hartafwijking 
die ooit was bestudeerd (n=1302). De meest voorkomende cardiale complicaties tijdens de 






hartfalen (2%). Factoren die onafhankelijk geassocieerd waren met cardiovasculaire complicaties 
bij de moeders waren de aanwezigheid van cyanotische hartafwijkingen (zowel gecorrigeerd 
als ongecorrigeerd), het gebruik van cardiale medicatie vóór de zwangerschap, obstructie van de 
linker harthelft, de aanwezigheid van een mechanische kunstklep en een systemische of pulmonale 
atrioventriculaire klep insufficiëntie. De meest voorkomende obstetrische complicatie was een 
hypertensieve aandoening van de zwangerschap (12%). De meest voorkomende complicaties bij het 
kind waren vroeggeboorte (12%), een te laag geboortegewicht voor de duur van de zwangerschap 
(14%) en sterfte (4%). Onafhankelijke voorspellers van complicaties bij het kind waren: moeders 
met cyanotische hartafwijkingen, de aanwezigheid van een mechanische kunstklep bij de moeder, 
rokende moeders, een meerling zwangerschap en het gebruik van cardiale medicatie door de moeder. 
Voorts werd het meest gebruikte model voor de schatting van het zwangerschapsrisico bij vrouwen 
met een hartaandoening (CARPREG risico score) gevalideerd. We vonden dat de CARPREG score 
het risico op cardiovasculaire complicaties bij vrouwen met een aangeboren hartafwijking overschat 
en stelden een nieuw predictie model voor, dat voor vrouwen met een aangeboren hartafwijking 
meer specifiek is.
Het TWEEDE DEEL van dit proefschrift beslaat de prospectieve beoordeling van voorspellers van 
complicaties tijdens de zwangerschap bij vrouwen met een aangeboren hartafwijking. 
Hoofdstuk 4 beschreef het ontwerp en de ratio achter de prospectieve ZAHARA II studie, die 
werd ontworpen om te beoordelen of veranderingen in de cardiovasculaire, hemodynamische, 
neurohumorale parameters en uteroplacentale Doppler flow patronen tijdens de zwangerschap bij 
vrouwen met een aangeboren hartafwijking verschilden van gezonde vrouwen, die vergelijkbaar waren 
qua leeftijd en het aantal doorgemaakte zwangerschappen. Een ander doel van de ZAHARA II studie 
was om de interactie te onderzoeken van deze veranderingen met het voorkomen van cardiovasculaire 
en obstetrische complicaties evenals complicaties bij het kind. Ten slotte werd de ZAHARA II studie 
ontworpen om de bestaande risicoschattingsmodellen te vergelijken en prospectief te valideren in 
een cohort vrouwen met een aangeboren hartafwijking. In hoofdstuk 5 werden de verschillende 
beschikbare risicoschattingsmodellen gevalideerd en onderling vergeleken aan de hand van de 
ZAHARA II populatie. In deze prospectieve studie hebben we de uitkomst van 191 zwangerschappen 
bepaald. De ZAHARA I en CARPREG cardiovasculaire risico scores werden berekend voor elke 
zwangerschap, evenals het totaal aantal cardiovasculaire of kind risico voorspellers van deze en 
andere studies gecombineerd. Zwangerschappen werden ook ingedeeld volgens de gemodificeerde 
indeling van de Wereld Gezondheid Organisatie (WHO) voor maternale cardiovasculair risico en 
volgens ziekte complexiteit. Maternale cardiovasculaire complicaties vonden plaats in 10% van de 
zwangerschappen. Bij 33% van de zwangerschappen vond een complicatie bij het kind plaats. Zowel 
cardiovasculaire complicaties als complicaties bij het kind namen toe met toename van de ‘ZAHARA I’ 
en de ‘CARPREG´ risico scores, een hogere totaal aantal ‘cardiovasculaire’ of ‘kind’ risico 
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voorspellers, hogere ‘WHO klasse’ en grotere ‘complexiteit van de hartafwijking’. Bij het vergelijken 
van de 5 individuele risicoschattingsmodellen, bleek de gemodificeerde WHO classificatie het meest 
adequate individuele risicoschattingsmodel voor de beoordeling van het cardiovasculaire risico in 
de ZAHARA II cohort. Bij de vergelijking van risicoschattingsmodellen voor het voorspellen van 
complicaties bij het kind was het verschil in ‘area under the curve’ zeer klein tussen totaal aantal 
kind complicatie voorspellers, ZAHARA I risicoscore en totaal aantal CARPREG risico punten. 
Een combinatie van de risicofactoren van ZAHARA I en CARPREG gaf de grootste ‘area under the 
curve’ voor het voorspellen van complicaties bij het kind. In hoofdstuk 6 werden de hoofdresultaten 
van de ZAHARA II studie beschreven. Om aan te tonen dat bij vrouwen met een aangeboren 
hartafwijking de uteroplacentale doorbloeding wordt  gecompromitteerd door de cardiale dysfunctie 
en bijdraagt aan de toegenomen incidentie van complicaties, hebben we klinische (cardiovasculaire), 
biochemische en echocardiografische parameters evenals uteroplacentale doppler flow patronen van 
zwangere vrouwen met een aangeboren hartafwijking vergeleken met die van gezonde zwangere 
vrouwen en deze parameters tevens gerelateerd aan maternale en kind complicaties bij vrouwen 
met een aangeboren hartafwijking. We hebben 209 vrouwen met een aangeboren hartafwijking en 
70 gezonde vrouwen geïncludeerd in deze studie. Cardiovasculaire parameters (NT-proBNP, 
linker en rechter ventrikel functie) verschilden tussen beide groepen. Uteroplacentale Doppler flow 
parameters waren slechter bij vrouwen met een aangeboren hartafwijking dan bij gezonde vrouwen. 
Vrouwen met een aangeboren hartafwijking hadden vaker obstetrische complicaties evenals meer 
complicaties bij hun kinderen dan gezonde vrouwen (58,9% versus 32,9%, P<0,0001 en 35,4% versus 
32,9%, P=0,008). Een verminderde uteroplacentale Doppler flow was geassocieerd met een slechtere 
obstetrische en kind uitkomst bij vrouwen met een aangeboren hartafwijking. Een aantal abnormale 
cardiovasculaire parameters preconceptie en bij 20 weken zwangerschap waren geassocieerd met een 
verminderde uteroplacentale doorbloeding: een verhoogde NT-proBNP, een verminderde rechter 
kamer functie (‘tricuspid annular plane systolic excursion’ (TAPSE)) en systemische en pulmonale 
atrioventriculaire klepinsufficiëntie voorspelden een hogere arteria umbilicalis ‘resistance index’ bij 
32 weken zwangerschap. Een gecompromitteerde uteroplacentale doorbloeding zou dus een van de 
mechanismen kunnen zijn, betrokken bij de hogere incidentie van complicaties bij moeder en kind 
bij vrouwen met een aangeboren hartafwijking.
Toekomstperspectieven 
Tot nu hebben de meeste onderzoeken met betrekking tot zwangerschap bij vrouwen met een 
aangeboren hartafwijking zich gericht op de incidentie van zwangerschapscomplicaties. Sommige 
studies hebben zelfs voorspellers van een negatieve zwangerschapsuitkomst gevonden. In dit 
proefschrift zijn enkele nieuwe voorspellers toegevoegd aan de bestaande voorspellers. Daarnaast 
zijn er nieuwe risicoschattingsmodellen gemaakt die kunnen helpen bij de beoordeling van 
vrouwen die een verhoogd risico hebben op complicaties in de zwangerschap. Er zijn ook diverse 






worden en daardoor de zwangerschapsuitkomst bij vrouwen met een aangeboren hartafwijking. Om 
de risicoschatting bij vrouwen met een aangeboren hartafwijking verder te verbeteren in de toekomst 
is het belangrijk om voorspellers verder te specificeren en risicomodellen te verder te ontwikkelen 
voor de verschillende specifieke subgroepen van vrouwen met een aangeboren hartafwijking. Om 
dit te bereiken zijn grotere multicentrische cohort studies essentieel; daarom is het essentieel dat 
onderzoekers hun krachten bundelen. 
Cardiale parameters zijn niet alleen geassocieerd met cardiale uitkomst tijdens de zwangerschap. 
We hebben in de ZAHARA II studie ook aangetoond dat cardiale dysfunctie bij vrouwen met een 
aangeboren hartafwijking de uteroplacentale doorbloeding beïnvloedt. In de algemene zwangere 
bevolking is een abnormale uteroplacentale doorbloeding sterk geassocieerd met complicaties bij 
moeder en kind. Dit werd ook bevestigd in onze populatie zwangere vrouwen met een aangeboren 
hartafwijking. Verder onderzoek naar de relatie tussen de hartfunctie, danwel de vasculaire/
endotheliale functie met de uteroplacentale doorbloeding bij vrouwen met een aangeboren 
hartafwijking zou het mechanisme achter de vele complicaties bij vrouwen met een aangeboren 





















Velen hebben direct of indirect bijgedragen aan de totstandkoming van dit proefschrift. Ik wil 
iedereen hiervoor hartelijk bedanken. Daarnaast wil ik de volgende personen / groepen in het 
bijzonder noemen. 
Allereerst wil ik graag alle zwangere vrouwen (met en zonder aangeboren hartafwijking) die hebben 
deelgenomen aan de ZAHARA II studie bedanken. Zonder jullie onvoorwaardelijke deelname was 
het niet mogelijk geweest onze kennis over complicaties en voorspellers van complicaties bij zwangere 
vrouwen met een aangeboren hartafwijking te vergroten. Dankzij jullie medewerking hebben we 
kunnen aantonen dat er een relatie bestaat tussen de hartfunctie van de moeder en de complicaties 
die we zien bij zwangere vrouwen met een aangeboren hartafwijking en bij hun kinderen. Bedankt! 
Mijn promotoren prof. dr. D.J. van Veldhuisen en prof. dr. J.G. Aarnoudse:
Beste Dirk Jan, ik ben erg dankbaar dat je mijn promotor wilde zijn. Je bent als geen ander in staat 
een complex manuscript terug te brengen tot de kern. De promotiebesprekingen met jou waren vaak 
een extra duwtje in de rug en erg motiverend. Ik bewonder vooral ook je interesse in de persoon 
achter de promovendus. Ondanks dat congenitale hartziekten niet je primaire expertiseveld is, heb 
je de hoofdlijnen van mijn promotie traject zorgvuldig weten te bewaken. 
Beste Jan, dank voor je steun en begeleiding gedurende mijn promotie traject. Je heldere kijk op 
zaken en relativerend vermogen waren een welkome aanvulling gedurende mijn promotie traject. 
Mijn co-promotor dr. P.G. Pieper. Beste Els, ik zou je graag willen bedanken voor je voortdurende 
steun tijdens mijn promotie traject. Dankzij jou was het mogelijk om de ZAHARA II studie te 
coördineren, wat ik met veel plezier en dank heb gedaan. Dankzij jouw altijd positieve en motiverende 
instelling is mijn promotie tot een succes geworden. 
Dr. W. Drenthen. Beste Wim. Jij had de weg alvast geplaveid voor mij. Al was je geen co-promotor 
van me, ik heb erg veel aan je begeleiding ‘off the record’ gehad. Je steun en tips waren een welkome 
aanvulling evenals je altijd sappige verhalen. Ik ben je er veel dank voor verschuldigd. 
De leden van de leescommissie, prof. dr. C.M. Bilardo, prof. dr. R.M.F. Berger en prof. dr. T. Ebels 
wil ik graag bedanken voor hun kritische beoordeling van mijn proefschrift. 
Prof. dr. H.L. Hillege. Beste Hans, ik wil je graag bedanken voor je begeleiding op het gebied van de 
epidemiologie en statistiek maar vooral ook voor je informele steun. Je kritische opmerkingen waren 






Alle co-auteurs van mijn artikelen wil ik graag bedanken voor hun bijdrage aan dit proefschrift.
Dr. Joost van Melle, drs. Marieke Ludwig-Ruitenberg, Rob Harleman, Irene Grabienski 
(mijn eerste echocardiografie lerares!) en vooral dr. Hans Hamer zou ik graag willen bedanken voor 
het beoordelen van de vele cardiale echo’s.
Ook de andere betrokkenen uit het Universitair Medisch Centrum Groningen wil ik graag bedanken 
voor hun bijdrage aan het tot stand komen van mijn proefschrift en voor de fijne samenwerking: 
dr. Elke Hoendermis, prof. dr. Adriaan Voors, drs. Krystyna Sollie, dr Arie van Roon, drs. Mieke 
Kerstjens-Frederikse en dr. Henk Groen. Alle echo/functielaboranten en secretaresses van de 
afdelingen cardiologie, de prenatale diagnostiek en de vaatfunctieafdeling in het UMCG en in het 
bijzonder Anke Rasker (Fietsergometrie is nog nooit zo fruitig geweest…) 
De medewerkers van de cardioresearch Peter, Geert, Karin, Anja, Carla, Greetje, Margriet, Carolien, 
Bernard en natuurlijk Trienke wil ik graag bedanken voor de fijne samenwerking en voor de gezellige 
momenten. 
De secretaresses van ‘de vierde’, Alma en Audrey, wil ik graag bedanken voor alle steun en hulp 
gedurende en in het bijzonder in het laatste deel van mijn promotietraject. 
Anke W.D. Bolt-Joldersma. Beste Anke, zo bescheiden als je bent: “ik doe gewoon mijn werk”, 
heb je me menigmaal uit de ‘penarie’ geholpen als er voor de zoveelste keer een echo verzet moest 
worden om wat voor reden dan ook. Mede dankzij jouw flexibele houding en inzet werd het 
inplannen en vooral verplaatsen van echo’s niet zo’n marteling. 
Onderzoek in de congenitale cardiologie is niet mogelijk zonder hulp van en samenwerking met de 
congenitale centra in den lande. 
Prof. dr. B.J.M. Mulder. Beste Barbara, het AMC was als een tweede thuishaven. Je stond vaak klaar 
voor een persoonlijk of meer inhoudelijk praatje in het AMC of op congres. Als je eigen pupillen 
naar een congres of cursus gingen, dacht je vaak ook aan mij. Dat heb ik altijd enorm gewaardeerd. 
De congenitale collega’s uit het AMC: Michiel, Paul, Carla, Jeroen, Mariëlle, Klaartje, Zehliya, Piet, 
Annelieke, Dounya, Mark en Teun, wil ik graag bedankten voor alle steun, hulp en vooral ook de 
gezelligheid in het AMC en op congressen! 
De ‘CONCOR dames’ Lia, Sylvia en Irene wil ik graag bedanken voor hun hulp bij het 
verzamelen van de data in en rond het AMC en voor hun luisterend oor. Dr. Berto Bouma en 
dr. Maarten Groenink wil ik graag bedanken voor het aandragen van patiënten voor mijn studie. 
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Rianne, bedankt voor het regelen van de echo’s op de meest onmogelijke momenten en vooral ook 
voor je hulp bij het verzamelen van de echodata in het AMC. Dr. Babette Braams-Lisman, dank voor 
je hulp bij het opzetten van het prenatale diagnostiek deel van de ZAHARA II studie in het AMC. 
Zuster Manja Bunschoten: Beste Manja, het is mede dank zij jouw inzet en gedrevenheid dat we een 
groot aanbod van patiënten hadden vanuit de gynaecologie in het AMC. Had Martijn echt zo vaak 
slapeloze nachten?
Dr. M.A. Oudijk: beste Martijn, bedankt voor je inzet en enthousiasme voor de ZAHARA II studie. 
Je bleek niet alleen een zeer kritische gynaecoloog met hart voor de cardiologie, je bleek ook nog erg 
gezellig te zijn: op congressen wist je veilloos waar ‘the place to be’ was…
Prof. dr. J.W. Roos-Hesselink. Beste Jolien, bedankt voor je steun en persoonlijke interesse. Je bent 
een gedreven onderzoeker en een inspirator voor menig onderzoeker in de dop. Ondanks je vreselijk 
drukke werkschema gaf je mij het idee dat je zeeën van tijd had als ik je sprak over een manuscript 
of over minder formele zaken op congressen. Hoe doe je dat toch?
Ook de andere leden van het congenitale team in het Erasmus MC wil ik graag bedanken voor hun inzet 
en hulp bij het tot stand komen van dit proefschrift: dr. Maarten Witsenburg en drs. Judith A.A.E. 
Cuypers en in het bijzonder de promovendi: Titia, Petra (Is er al Tom Tom in het Erasmus MC?) en Denise. 
Beste drs. Jérôme Cornette, bedankt voor de revisie van de vele ‘Dopplers’ in het Erasmus MC en je 
commentaren op mijn manuscripten. 
Dr. A.P.J. van Dijk en drs. W.M. Waskowsy. Beste Arie en Marc. In Nijmegen data verzamelen 
was als thuiskomen en erg vertrouwd. Bedankt voor jullie hulp bij het uitvoeren van de ZAHARA 
II studie. Arie, bedankt voor de prettige samenwerking en je snelle en opbouwende kritiek op de 
manuscripten. 
Ook de overige centra wil ik graag bedanken voor hun bijdrage aan mijn proefschrift:
LUMC: dr. Hubert Vliegen, dr. Monique Jongbloed, dr. Eduard Holman, Roderick Scherptong, 
Marjolein Verhart en prof. dr. Jos van Roosmalen.
Medisch Spectrum Twente: drs. Elly Wajon en dr. Lodewijk Wagenaar.
UMC Utrecht: dr. Gertjan Sieswerda en dr. Carla van Oppen.
Maastricht Universitair Medisch Centrum: drs. Jan Stappers en prof. dr. Marc Spaanderman 






Promoveren zou half zo leuk zijn zonder de steun en gezelligheid van je mede promovendi. 
De collega’s van het Triadegebouw wil ik graag bedanken voor de gezonde afleiding, de vele 
colarondjes om even de zinnen te verzetten, de humor als er weer eens een werkplek was in ingepakt 
in alu folie of afgescheiden door krantpapier, de uitstapjes, de congressen en ‘t Feithhuis. Ik heb 
een prachtige tijd gehad met jullie! In alfabetische volgorde: Anne, Arjen, Bart, Caroline, Chris, 
Daan, Frank, Hendrik, Hessel, Imke, Ismaël, Jan Pieter, Jardi, Jasper, Karim, Kevin, Lieuwe, Liza, 
Marcelle, Marieke, Marjolein, Marthe, Mirjam, Nicolas, Pieter, Pieter-Jan, Renée, Rob, Sandra, 
Sheba, Suzan, Willem-Peter, Wouter, Ymkje en Youlan.
‘Mijn’ studenten Rianne, Marlies en in het bijzonder Geraldine. Jullie hebben een bijzondere 
bijdrage geleverd aan dit proefschrift, waarvoor ik jullie graag wil bedanken. Marlies, veel succes 
met het voortzetten van de ZAHARA trein!
Mijn paranimfen Dinçer Balci en Lennaert Kleijn. Beste Dinçer. Je was altijd al mijn ‘partner in 
crime’ en ik ben heel erg blij dat je me op deze belangrijke dag wilt bijstaan!
Beste Lennaert, een betere kamergenoot kan een promovendus zich niet wensen. Je humor en 
onuitputtelijke enthousiasme zijn fantastisch. Net als je passie voor de fiets. Groningen-Zwolle doe 
ik echter liever toch met de trein dan op de fiets… 
De verloskundigen en echolaboranten van het Verloskundige Stadspraktijk Groningen en de overige 
verloskundige praktijken in de regio Groningen, Drenthe en Friesland: bedankt voor het aandragen 
van alle gezonde zwangere vrouwen en jullie hulp bij het verzamelen van de uitkomsten van de 
zwangerschap!
Natuurlijk mogen de huidige collega’s in de Isala Klinieken niet ontbreken in mijn dankwoord: jullie 
hebben me regelmatig gesteund en geholpen in de laatste fase van mijn promotie. Ik kijk uit naar een 
fantastische tijd met jullie in Zwolle. 
Vera Derks, wat zou de afdeling cardiologie in Zwolle zonder jou moeten. Dank voor je hulp en tips 
tijdens de voorbereidingen in de laatste fase van mijn promotie. 
De maatschap cardiologie in Zwolle en in het bijzonder de opleider Dr. A.R. Ramdat Misier wil ik 
graag bedanken voor het mogelijk maken om mijn medische carrière in de Isala Klinieken voort te 
mogen zetten. 
Mijn familie, vrienden, ouders en schoonfamilie: bedankt voor jullie onaflatende steun en interesse 
gedurende mijn onderzoek. Jullie steun was onontbeerlijk in de afgelopen 4 jaar. 
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Lieve Jeannine, ik weet niet hoe ik je zou kunnen bedanken voor je grenzeloze liefde, je begrip en je 
onvoorwaardelijke steun. Je hebt veel moeten opofferen in de afgelopen 4 jaar als ik weer eens dag en 
nacht aan een deadline werkte of als ik weer eens de hort op was om data te verzamelen of op congres was. 
Jij bent mijn grootste steun en motivator. Geen dal is te diep met jou aan mijn zijde. Ik hoop dat je 
nog lang en gelukkig aan mijn zijde wilt staan.
Lieve Elin, de ‘fakkel’ in ons leven. Zonder het zelf te beseffen ben jij mijn mooiste inspirator. Je hebt 
mij doen beseffen dat er meer is in het leven!
Hivyo, sasa ni wakati wa sherehe!
 









Behorende bij het proefschrift:
Pregnancy and Outcome in women with Congenital Heart Disease
door
Ali Balci
1.  Vrouwen met een gecorrigeerde tetralogie van Fallot hebben een verhoogd risico op cardiovasculaire en 
obstetrische complicaties tijdens de zwangerschap. (Dit proefschrift)
2.  Foetale en neonatale complicaties zijn bij vrouwen met een gecorrigeerde tetralogie van Fallot geassocieerd 
met cardiovasculaire complicaties in de zwangerschap. (Dit proefschrift)
3.  De CARPREG risico score overschat het risico op complicaties in een populatie vrouwen met een structureel 
aangeboren hartafwijking. (Dit proefschrift)
4.  De gemodificeerde WHO classificatie is het best beschikbare risicoschattingsmodel voor het inschatten van het 
cardiovasculaire risico bij zwangere vrouwen met een aangeboren hartafwijking. (Dit proefschrift)
5.  De aanwezigheid van een mechanische klepprothese bij vrouwen met een aangeboren hartafwijking is sterk 
geassocieerd met cardiale complicaties in de zwangerschap. (Dit proefschrift)
6.  Zwangere vrouwen met een aangeboren hartafwijking hebben een hogere weerstand in de uteroplacentale vaten en 
slechtere cardiovasculaire parameters dan gezonde zwangere vrouwen. (Dit proefschrift)
7.  De weerstand in de uteroplacentale vaten is bij vrouwen met een aangeboren hartafwijking gerelateerd aan de 
cardiovasculaire functie van de moeder en tevens een voorspeller van complicaties bij moeder en kind. (Dit proefschrift)
8. Hiç bilenlerle bilmeyenler bir olur mu? (Kur’an-ı Kerim, 39:Zümer;9)
9. Varium et mutabile semper femina (Publius Vergilius Maro, Aeneas 4, 569-570)
10. Vergissen is menselijk. Volharden is des duivels (Seneca 4 v. Chr.-65 n. Chr.)
11. Liefde vermenigvuldigt zich als je het deelt; net als kennis.
12. Leren ‘Nee’ zeggen is een belangrijk onderdeel van het promotietraject.
13.  Mistakes are all right, but failure is not. Failure is jus a mistake you cannot recover from. 
(NASA, lessons in project management)
14.  An expert is a man who has made all the mistakes that can be made in a very narrow field. (Niels Bohr, 1885-1962)
